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ABSTRACT 
 
P. aerguinosa is a serious human bacterial pathogen. This thesis describes attempts to use 
structural biology to identify new starting points for drugs against P. aerguinosa .A number of 
fragment-based screening techniques were used in order to identify potential inhibitors to P. 
aerguinosa RmlA protein, the first enzyme in the L-Rhamnose pathway. A 500 “Rule of 3” 
Fragment Library (Maybridge) was investigated. The first approach was the application of 
Differential Scanning Fluorimetry (DSF) approach to detect ligands that bind and stabilize 
RmlA protein. The stabilisation of RmlA was determined by thermal unfolding in the presence 
of each of the 500 compounds. 21 of those compounds were found to increase the protein 
stability. The library was then screened by NMR spectroscopy for binding to RmlA. Two 
techniques were evaluated STD and WaterLOGSY. 106 compounds gave positive results in 
both NMR experiments. These hits were then tested by a simple STD competition binding with 
dTTP, a natural RmlA substrate, in order to identify those binding at the active or allosteric 
site. 21 out of the 106 compounds were observed to compete with dTTP. The results were 
compared to the results of the DSF screening. Compounds that tested positive in the dTTP 
competition binding STD experiment and in the DSF screening were tested for their   ability to 
inhibit RmlA in a biological assay. A coupled enzyme assay was used to monitor RmlA 
activity. Only one compound, 3-pyridin-3-ylaniline, showed significant inhibition of the 
enzyme activity.  
The PA1645 protein from P. aerguinosa has been identified as essential. The protein was 
overexpressed, purified and crystallised. Data were collected at Diamond on beamline IO3 and 
phases were determined by S-SAD at a wavelength of 1.6Å. Final coordinates have been 
deposited in the protein data bank under entry code 2XU8. The structure has 3 molecules in the 
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asymmetric unit. There is some ambiguity as to the validity of the proposed trimeric 
arrangement, with results from solution and crystal disagreeing. 
Fragment-based screening approach has been applied to RmlA protein, using the DSF 
technique, a number of ligand-based NMR experiments and a coupled enzyme biological 
assay. 3-pyridin-3-ylaniline was the only compound that showed significant inhibition of the 
enzyme activity. The structure of PA1645 from P. aerguinosa has been solved. This work will 
help to design new drugs to combat multi-drug resistant P. aerguinosa and MTB.  
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CHAPTER ONE 
Introduction 
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1.1. Antibiotics resistance  
Nowadays, bacterial resistance to antibiotics is an ever-increasing worldwide concern. A 
fundamental problem leading to such resistance is the irrational use of antibiotics. In fact, 
prolonged or inadequate dosing of antibiotics may result in the selection of multidrug resistant 
isolates, as these bacteria survive and replicate depending on a number of factors including 
antibiotic use (Henderson, 2006). The misuse and overprescribing of antibiotics is a common 
practice in many parts of the world, especially developing countries where the supply of these 
agents is unregulated (Hart and Kariuki, 1998).  
Highly detailed molecular structures of macromolecules are being determined by X-ray 
crystallography at an ever increasing rate. This is important in the clarification of enzymatic 
mechanisms, for example. Knowledge of the three-dimensional structure of target proteins is 
also essential for structured based approach for design of new inhibitors against viral and 
bacterial diseases (Blundell, 1996).   The discovery of new drugs offers one solution to the 
frightening emergence in both infection rates and antimicrobial drug resistance. Infections 
arising from Gram-negative pathogenic bacteria present a major concern in Public Health 
(Nadeem et al., 2009). P. aeruginosa is amongst the most significant of such pathogens. This is 
a particular problem in Europe with a larger aging population and an increasing number of 
immunocompromised individuals. There is a need for a faster rate of structural biology studies 
allowing bacterial protein targets to be characterised to serve as leads in structure-guided drug 
design.  
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1.2. Pseudomonas aeruginosa  
In 1862, Luke first reported Pseudomonas aeruginosa (P. aeruginosa) in human infections. 
Later, in 1882, the bacterium was first isolated by Gessard, who called it Bacillus pyocyaneus 
(Lyczak, 2000). P. aeruginosa is a Gram-negative opportunistic pathogen with minimal 
nutritional requirements and can tolerate a wide variety of physical conditions. This ubiquitous 
free-living bacterium is found in most moist environments (Moynie et al., 2013).  
There are more than 140 species of the pseudomonas genus, most of which are saprophytic and 
over 25 species of those are linked to humans (Nadeem et al., 2009). The majority of 
pseudomonas known to cause disease in humans are linked to opportunistic infections. 
Examples of those species include P. aeruginosa, P. fluorescens, P. putida, P. cepacia, P. 
stutzeri, P. maltophilia, and P. putrefaciens. Nearly 80 percent of pseudomonads recovered 
from clinical specimens are P. aeruginosa and P. maltophilia. P. mallei and P. pseudomallei 
are the only two species that produce specific human diseases glanders and melioidosis 
(Nadeem et al., 2009).  
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Figure 1.1: Microscopic photograph of P. aeruginosa (http://www.pseudomonas.com)  
P. aeruginosa rarely causes disease in healthy individuals. However, it is a major cause of 
infection in hospitalised and immunocompromised patients. This includes debilitated patients 
due to neutropenia undergoing chemotherapy and patients with immunosuppression such as 
AIDS (Lyczak, 2000; Cryz et al., 1984). Chronic lung infection in cystic fibrosis patients, 
bacteraemia in severe burn victims, urinary-tract infections in catheterised patients, hospital 
acquired pneumonia in patients on respirator and acute ulcerative keratitis in users of extended-
wear soft contact lenses are of the most commonly known human diseases caused by P. 
aeruginosa (Lyczak, 2000; Cryz et al., 1984). According to data from The National 
Nosocomial Infection Surveillance system P. aeruginosa causes nosocomial infections which 
account for 20% of pneumonia and 16% of urinary tract infections (Worlitzsch et al., 2002). In 
US hospitals P. aeruginosa accounts for 0.4 percent (4 per 1000 discharges) of infections on 
average, and the organism is the fourth most commonly isolated nosocomial pathogen 
accounting for 10.1 percent of all hospital-acquired infections (NCCLS, 2003).  
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Treatment of infections caused by P. aeruginosa can be very difficult as this organism in 
particular demonstrates all known enzymic and mutational mechanisms of bacterial resistance, 
which makes it a phenomenon of antibiotic resistance (Pechere and Kohler, 1999; Nadeem et 
al., 2009). P. aeruginosa is intrinsically resistant to most antimicrobial agents (Mesaros et al., 
2007; Nadeem et al., 2009). Intrinsic resistance consists of the inherent structural or functional 
characteristics that exist in the average strain of a given species and provide it with an innate 
ability to resist a particular antimicrobial agent irrespective of antibiotic exposure (Hancock, 
1998). The basis for the high intrinsic resistance of P. aeruginosa is its low outer-membrane 
permeability to the uptake of antibiotics and substrate molecules. The movement of small 
hydrophilic molecules such as β-lactams into the cell is restricted to a small portion of the 
outer-membrane (mainly the water-filled channels of porin proteins) (Hancock, 1998). 
Although this semi-permeable barrier property of the outer- membrane is true for all Gram-
negative bacteria, it is especially true in the case of P. aeruginosa, which has an outer-
membrane that is 12 to 100-fold less permeable than that of Escherichia coli (E. coli) for 
example (Nikaido and Hancock, 1986). 
P. aeruginosa also has an acquired resistance to antimicrobials. This type of resistance arises as 
a result of the exposure of a strain to a number of inducing conditions that can include 
antibiotics. Acquired resistance does not involve an observable change in genotype. In the case 
of P.aeruginosa a major difference has been observed between in vitro minimum inhibitory 
concentrations (MICs) and in vivo efficacy, which means that cure is not achieved even if 
antibiotic concentrations are reached during therapy (Hancock, 1998; Strateva and Yordanov, 
2009). Potential causes of the acquired resistance of P.aeruginosa to antimicrobials include the 
growth rate and growth phase of the organism itself.  The killing of the latter by antimicrobials 
such as tobramycin and ciprofloxacin was shown to be highly dependent on the growth phase 
of the bacteria and required concentrations of the antibiotics that were higher than the in vitro 
17 
 
MIC.   Although difficult to explain, this acquired resistance could be based on the fact there is 
limited oxygen availability at higher culture densities which may affect the action of antibiotics 
that require active electron transport for cellular uptake (Davey et al., 1988; Bryan, 1991; 
Hancock, 1998) 
The acquired resistance of P.aeruginosa is unstable and the organism will revert to full 
susceptibility when the inducing environmental factors are removed. However, the intrinsic 
resistance of the bacterium can be coupled with genetic resistance which involves the stable 
acquisition of a drug resistance plasmid, or new genetic information as a result of mutation of 
an existing gene product or control mechanism. These genetic resistance mechanisms affect the 
most frequently administrated antipseudomonal antibiotics: β-lactams, aminoglycosides and 
fluoroquinolones (Strateva and Yordanov, 2009). In the case of aminoglycosides, for example, 
broad range resistance mechanisms have been described. Enzyme modification is one of the 
major mechanisms reported, which involves the acquisition of certain plasmids encoding for 
enzymes that attach a phosphate, adenyl or acetyl radical to the antibiotic molecule. This 
results in a reduced binding affinity of the modified antibiotics to the target in the bacterial cell 
(Llano-Sotelo et al., 2002). The bacterium also has in its chromosome an aminoglycoside 
resistance gene, aphA, which can be activated by mutation (Okii et al., 1983).  
Fluoroquinolone-resistant mutants in P. aeruginosa result from two major mechanisms. The 
first one involves structural changes in target enzymes, which results from target-site mutations 
in DNA gyrase (Yoshida et al., 1990). The second one is efflux mutations. In P. aeruginosa, 
four well known genetically different efflux systems were identified, each of which has a 
preferential set of antimicrobial agent substrates. However, the fluoroquinolones were found to 
be  universal substrates for each of these efflux pumps (Poole et al., 1993; Masuda et al., 1995; 
Masuda et al., 2000).The naturally occurring chromosomal AmpC β-lactamase (also known as 
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cephalosporinase) coupled to  the low membrane permeability of P. aeruginosa contribute to a 
great extent to the organism’s natural resistance to β-lactams. (Nordmann and Guibert, 1998; 
Hancock and Speert, 1996). There are uncommon genetic resistance mechanisms that affect β-
lactams which include altered outer-membrane permeability, which mainly involves the loss of 
the major porin protein named OprF.  Only a modest increase in resistance is observed with 
such mutations and does not always affect β-lactams themselves. Modification of the target 
site, penicillin-binding protein (PBP), is another rare genetic resistance mechanism observed in 
clinical, animal model and selected laboratory isolates (Hancock and Speert, 1996; Malouin 
and Bryan, 1986). Examples include altered PBP-4s with low affinity which were reported 
after imipenem treatment and modified PBP-3s, which results in an increased resistance to 
many anti-pseudomonal β-lactams (Gotoh, 1990; Pechere and Kohler, 1999). 
With fewer antimicrobial agents being developed, resistance in this organism can develop very 
rapidly at a much faster rate. This, combined with weakened host defences and the production 
of extracellular bacterial enzymes and toxins, results in a high mortality rate from infections 
due this notorious bacterium, which can go up to 40–50% (Shahcheraghi et al., 2003).  
 
1.3. Mycobacterium tuberculosis  
Mycobacterium tuberculosis (MTB) is a pathogenic bacterial species in the genus 
Mycobacterium. In 1882, Robert Koch first identified the species as the causative agent of 
most cases of tuberculosis (TB) (Salo et al., 1994). It is a primarily a pathogen of the 
mammalian respiratory system, infecting the lungs (figure 1.2). MTB is transferred in the form 
of aerosol droplets that are inhaled by the lungs. In most cases the infection is cleared and 
bacteria are destroyed by macrophages or driven into a chronic, latent state that is 
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asymptomatic and potentially long lasting. In the active state the bacteria can multiply and 
destroy blood vessels and lung tissues (Davidow et al., 2005). TB is diagnosed using tuberculin 
skin test, acid-fast stain, and chest radiographs. It is estimated that one-third of the world’s 
population has been in contact with the pathogen, but approximately 90% of infected persons 
are clinically asymptomatic (Fremond et al., 2004). According to statistics produced by the 
World Health Organization (WHO) two billion people are infected with (MTB), with nine 
million new active TB cases annually (Spigelman, 2007; World Health Organization, 2010).  
WHO estimates that about two million TB infected individuals die annually, with 25 % of the 
deaths occurring in patients who are co-infected with human immunodeficiency virus (Lawn 
and Zumla, 2011). Drug-resistant MTB strains appear spontaneously at a predictable rate 
(Gillespie, 2002). Acording to WHO global data about 17% of MTB strains in new, previously 
untreated cases are resistant to at least one first-line drug. Although resistance to any TB 
medication can occur, resistance to isoniazid, one of the most effective currently available 
drugs, is most common (10%) (World Health Organization, 2008). Strains resistant to more 
than one drug for example isoniazid and rifampin both, and possibly resistant to other drugs, 
are named multidrug resistant (MDR) (World Health Organization, 2008).  Extensively drug 
resistant (XDR) is defined as MDR strains that are also resistant to fluoroquinolones and at 
least one of the three injectable second line drugs (Makarov et al., 2009). Second-line drugs 
include aminoglycosides, cyclic polypeptides, thioamides, serine analogues, and salicylic acid 
derivatives to which resistance have been demonstrated in vitro studies (Udwadia et al., 2012; 
Velayati et al., 2009). 
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Figure 1.2: Mycobacterium tuberculosis (from www.sciencesource.com)  
 
The long doubling time of MTB strains represents a considerable difficulty in working with the 
pathogen which divides every 15–20 hours. This is relatively slow compared to other bacteria 
with division times measured in minutes. E. coli for example can divide roughly every 20 
minutes (Dye et al., 2002). 
The mycobacterial cell wall of the TB bacilli represents an attractive target for drug discovery. 
The wall core is composed of three interconnected macromolecules (figure 1.3). The outermost 
is a lipid layer that consists of branched fatty acids called the mycolic acids. The middle 
component, arabinogalactan (AG), is a polymer composed of D-galactofuranosyl and D-
arabinofuranosyl residues. AG is linked to peptidoglycan, the innermost of the three 
macromolecules, by a linker disaccharide α-L-rhamnosyl-(13)-α-D-N-acetyl-glucosaminosyl-
1-phosphate, to the 6 position of a muramic acid residue in the peptidoglycan (Ma et al., 2001).  
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Figure 1.3: Mycobacterium tuberculosis cell wall structure and the dTDP-L-rhamnose 
pathway (taken from Ma et al., 2001).  
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1.4. L-Rhamnose Pathway  
As shown in figure 1.3, AG is crucial for mycobacterial viability as it links the lipid layer to 
peptidoglycan. It also shows the role of the rhamnosyl residue in the attachment of AG to 
peptidoglycan. L-Rhamnose is a sugar not found in humans. However, it is commonly present 
in the cell wall of other Gram-positive bacteria and as a component of O antigens in Gram-
negative bacteria such as P. aeruginosa. L-Rhamnose is synthesized in nature from thymidine 
triphosphate (TTP) and glucose-1-phosphate via a single pathway involving four enzymes 
(figure 1.3) (Ma et al., 2001). RmlA (glucose-phosphate thymidylyltransferase), a 
homotetramer, is the first enzyme in the L-Rhamnose pathway. It transfers thymidyl 
monophosphate nucleotide (TMP) to glucose-1-phosphate, forming dTDP-D-glucose 
(Blankenfeldt et al., 2000a). The latter is dehydrated to dTDP-6-deoxy-D-xylo-4-hexulose by 
RmlB (dTDP-D-glucose 4,6-dehydratase), the second enzyme in the pathway (Allard et 
al.,2001). The third enzyme in the pathway is a dimer, RmlC (dTDP-6-deoxy-D-xylo-4-
hexulose 3,5-epimerase). It catalyses a double epimerisation at C3 and C5 to form dTDP-6-
deoxy-L-lyxo-4-hexulose (Dong et al., 2003). RmlD (dTDP-6-deoxy-L-lyxo-4-hexulose 
reductase), a monomer, is the final enzyme for the L-Rhamnose pathway reducing the C4 keto 
group of dTDP-6-deoxy-L-lyxo-4-hexulose to a hydroxyl, forming dTDP-L-rhamnose 
(Blankenfeldt et al., 2002). Knockout studies have shown that if any of the four Rml genes are 
deleted the cell-wall polysaccharide synthesis is inhibited and the bacteria is no longer able to 
sustain infection, which makes this single L-Rhamnose pathway a suitable target for drug 
discovery (Dong et al., 2003).  
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1.5. Drug discovery techniques  
The examples of drug-resistant organisms discussed above demonstrate the need for the 
development of new therapeutic agents. The fragment-based drug discovery (FBDD) is 
currently predominant in pharmaceutical research and biotechnological industries, with over a 
decade of practical experience and theoretical analysis. Leads derived from high throughput 
screening (HTS) of large compounds had a low success rate in clinics. Better understanding of 
the reasons for such failure influenced to a great extent the fragment based drug discovery 
fields and formed the basis of its underpinning logic (Siegal et al., 2007).  
Compared to HTS, FBDD has a number of attractive features. First, the essence of this 
approach is the use of low molecular weight fragments, usually less than 250 Dalton (Goddette, 
2006; Rees et al., 2004). In general, reducing the size of a large complex molecule is more 
difficult than building up a new one (Erlanson, 2006). Therefore, this feature makes the 
subsequent chemical optimization of the drug easier, allowing hence the production of leads 
with high ligand efficiency (LE) and molecular weights within the desired range (Liu et al., 
2003). The concept of LE can be used to determine the potency of hits during lead 
identification stage and decide whether an increase in molecular size is necessary and can be 
justified by significant gains in potency. LE can be defined as: 
   
   
   
 
          
   
               
where ΔG is the free energy of binding of the ligand for a specific protein, HAC is the number 
of heavy atoms in the ligand, and Kd represents the dissociation constant for the protein-ligand 
complex (the half maximum inhibitory concentration, IC50, is often used instead of Kd) 
(Murray et al., 2010) 
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Second, the number of compounds screened is smaller, usually in the range of a hundred to a 
few thousands (Goddette, 2006; Rees et al., 2004). This can be explained by the fact that these 
compounds are simpler in structure, with a higher probability of binding to target protein-
binding site than large complex molecules (Lesuisse et al., 2002). They are small enough to 
reduce the probabilities of unfavourable interactions (electronic or steric) to a minimum. Third, 
unlike most other techniques, FBDD detects compounds that bind with low affinity (100 μM to 
10 mM) (Goddette, 2006). Structural information about these weak binding interactions can be 
obtained via techniques such as X-ray crystallography, NMR and others (Congreve et al., 
2003b). 
 
1.6. FBDD approaches  
Once structural information about weak binding interactions is available, fragments enter the 
chemical optimization stage where they are expanded in an iterative process, until a strong 
binding drug candidate is developed (Wolfson, 2006). Fragment-based approaches used in lead 
discovery can be classified into four categories. The first and most useful one is fragment 
evolution (figure 1.4) which involves the use of a direct binding technique, given that there is 
some information on the binding mode of the initial fragment. This information allows the 
construction a more complex molecule with additional functionality in order to bind to adjacent 
regions of the protein active site and render the initial fragment into a tighter-binding molecule 
(Erlanson, 2006).  
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Figure 1.4: Shematic representation of fragment evolution. (a) Fragment 1 binds to the 
receptor at one site. (b) A more complex molecule “lead” builds away from the original 
fragment and stregnthen the contact with upper surface and then grows into an adjacent pocket 
(Rees et al., 2004).  
 
The second approach is fragment linking (figure 1.5), where two or more fragments that are 
identified to bind to separate but proximal parts of the binding site are chemically linked 
together to achieve a super additivity effect. The joined molecule is larger with a higher affinity 
binding. For this process to be efficient, not only the starting fragments need to be identified, 
but also a process by which these fragments can be appropriately linked in an efficient way.  
 
Figure 1.5: Diagram illustrating fragment linking approach. (a) Fragment 1 binds one part of 
the receptor’s binding site. (b) Fragment 2 binds to the receptor at a proximal part of the 
binding site. (c) Lead molecule spans both parts of the binding site as a result of joining 
fragments 1 and 2 by a linking group (Rees et al., 2004).  
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The third approach is fragment self-assembly (figure 1.6), where fragments with 
complementary functional groups are able to react together (self-assemble), in the presence of 
the protein target (the template molecule). The template protein, without being covalently 
bound to the inhibitor, contributes to the self-selection and catalyses the synthesis of its own 
inhibitor (Rees et al., 2004). This self-screening helps accelerating the identification of lead 
compounds for drug discovery (Ramström and Lehn, 2002). 
 
Figure 1.6:  Schematic illustration of fragment self-assembly approach. (a) Fragments 1 and 2 
bind to receptor sites at the same time. The two fragments possess proximal groups that are 
able to react with each other in the presence of the template molecule. (b) The resulting lead 
molecule is formed in the active site (Rees et al., 2004). 
 
The concept of using fragments that spontaneously assemble through reversible chemical 
reactions, in the presence of a template molecule (such as a protein), to generate libraries of 
chemical compounds, is referred to as dynamic combinatorial chemistry (Ramström and Lehn, 
2002). The latter is a recently introduced supramolecular (involving several molecules) 
approach that is becoming a large and growing field (Rees et al., 2004). The self-assembly and 
the continuous interconversion between the library constituents through reversible chemical 
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reactions, virtually embraces all possible combinations allowing the generation of virtual 
combinatorial libraries (figure 1.7) (Ramström and Lehn, 2002).   
 
Figure 1.7: Diagram illustrating the concepts behind dynamic combinatorial chemistry and 
virtual combinatorial libraries. A true dynamic library of interchanging ligands is represented 
with 'keys' at the top of the diagram. These keys are created through reversible exchange of a 
limited number of initial key building blocks. In the presence of a receptor (a molecular 'lock') 
the best binder is selected. The library is then forced to rearrange in a way such as more species 
of this ‘key’ member are produced. The bottom of the diagram describes the establishment of a 
virtual combinatorial library, the components of which become detectable only in the presence 
of a template receptor (selector) (Ramström and Lehn, 2002).  
 
The fourth category of fragment-based approaches is fragment optimisation (figure 1.8), where 
fragment properties are modified to optimise its drug-like properties (other than binding 
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affinity). This may include selectivity, cell based activity, oral activity or efficacy (Rees et al., 
2004).  
 
Figure 1.8: Diagram illustrating fragment optimisation approach. (a) Lead molecule 1 as 
discovered by fragment-based approach. (b) Lead molecule 3 resulting from modification of 
the overall physical properties of lead molecule 1 with aim of improving a particular property.  
 
1.7. Fragment library design  
1.7.1. Fragments key properties  
Drugs that pass through the fragment optimisation stage undergo years of intensive 
toxicological and clinical-efficacy studies. If successful, the drugs are then, finally, accepted by 
regulatory and paying bodies. Most drug candidates that survive those stages have a set of 
physico-chemical key properties that fall within a certain ‘drug-like space’. A number of cut-
off values have been used to define such a space, most importantly the values highlighted by 
the medicinal chemist Christopher Lipinski and his colleagues in the ‘rule of five’ (Hughes et 
al., 2008; Luker et al., 2011).  
Lipinski’s rule of five provides the original framework for the development of drug candidates 
that are orally bioavailable, in order to enhance their pharmacokinetic, absorption, distribution, 
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metabolism, and excretion properties (Lipinski et al., 1997). According to this rule, a 
compound intended for oral delivery must have no more than five hydrogen-bond donors (OH 
and NH groups), a maximum of ten hydrogen-bond acceptors (notably N and O), a molecular 
mass less than 500 Dalton, and a partition coefficient LogP (a measure of the molecule’s 
lipophilicity) under five. The origin of the rule’s name “Five” is from the fact that all numbers 
in the rule are multiples of five (Rees et al., 2004; Goddette, 2006). Lipinski’s rules have been 
enhanced by more recent analysis. According to these analyses the number of rotatable bonds 
(NROT) is an important parameter where an upper limit of seven rotatable bonds is optimal for 
oral bioavailability (Rees et al., 2004). Another key property (rule) is the polar surface area 
(PSA) which it is thought that molecules that are passively absorbed with a PSA of 110-140 Å2 
have a low oral bioavailability (Congreve et al., 2003a). In the light of these considerations, 
studies indicate that fragments seem to obey a “Rule of 3”. In this rule, as proposed by Astex 
Therapeutics, molecular weight is < 300 Dalton, ClogP ≤ 3, H-bond donors < 3, hydrogen bond 
acceptors < 3, NROT < 3, and a total polar surface area (TPSA) < 60Å2 (Goddette, 2006). This 
“Rule of 3” could be a useful selection tool when building fragment libraries for efficient lead 
discovery (Congreve et al., 2003a).  
 
1.7.2. Library design  
Fragments chosen in this research are “Rule of 3” compliant and a lower limit of 150 Da for 
general use, diversity library has also been proposed (Babaoglu and Shoichet, 2006). This limit 
was suggested to minimise the fragments chances of binding in multiple orientations, which is 
the case with smaller less complex fragments containing single rings with small substituents 
(Xu, 2002). Water solubility of the fragments is another important property to consider when 
building a fragment library, since fragments will have to be screened at high concentration in 
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aqueous buffer due to their low binding affinity. It can be difficult to predict the solubility of 
the fragment in crystallisation experiments (Jacoby et al., 2003; Baurin et al., 2004; Lepre, 
2001). Water solubility can be estimated by applying cut off values based on experience for 
predictable properties such as CLogP and the number of H-bond donors and acceptors (Siegal 
et al., 2007). There is no simple correlation between water solubility, number of H-bond donors 
and number of H-bond-acceptors. The absence of robust computational methods means one 
must determine the solubility of a given fragment experimentally (Baurin et al., 2004). 
Furthermore, it is preferable that the fragment possesses a chemical “handle” for further 
elaboration, but should not be too reactive to avoid a covalent with the protein target (Siegal et 
al., 2007).  
The above analysis addresses the “property space” of the fragment. A further analysis is needed 
to select fragments with a good chance to bind to a target protein. For example, the chemical 
tractability of the fragment can be analysed, where the presence of linker functionality is 
required. Building blocks such as those used in combinatorial chemistry could be suitable 
fragments. This approach can be further elaborated by using masked linker groups. 
The size of the actual fragment library is also important. This size varies according to the 
method used (Siegal et al., 2007; Congreve et al., 2003b). More importance is being given to 
the contents of the screening libraries as researchers gain experience in the FBDD field. Unlike 
the large libraries used in HTS, FBDD libraries only consist of a few hundred or thousand 
compounds, which makes them far easier to curate (Baker, 2013). Current FBDD libraries 
include more diversely shaped compounds whereas they were composed mainly of compounds 
that could be purchased from chemical suppliers. Astex, for example, is currently building its 
sixth-generation library (Baker, 2013).  
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1.7.3. Quantitative estimate of drug-likeness (QED) score  
The pharmaceutical industry is facing productivity challenges due to the low number of new 
drug approvals relative to the high costs of research and development investment. The high 
attrition rate (96%) of compounds that enter clinical trials puts pressure on scientists to 
improve the quality of target for this industry to survive in the longer term (Bunnage, 2011). 
Hopkins and colleagues contributed to the enhancement of guidelines for drug-likeness by 
providing a quantitative estimate that analyses a combination of a molecule’s physical 
properties. Their approach allows ranking molecules in order of desirability by defining a 
single, continuous scale. Desirability functions were defined for eight physical properties. This 
includes the number of groups in the molecule known to cause toxicity, the number of aromatic 
rings, the polar surface area and the number of rotatable bonds in a molecule. The four Lipinski 
properties were also taken into account. The functions encompass the full distribution of each 
physical property and generate a scale of continuous quantitative estimate of drug-likeness 
(QED) from most to least drug-like (Bickerton, 2012). By computing drug-likeness on a single 
quantitative scale, this method offers a “holistic” and more balanced analysis than other 
approaches (Leeson, 2012). 
 
1.8. Screening techniques  
1.8.1. X-ray crystallography  
This technique has been used by a number of companies, such as Astex Therapeutics 
(http://www.astex-therapeutics.com) and SGX Pharmaceuticals (http://www.sgxpharma.com), 
to screen for small molecules with very weak binding affinity. These molecules were then 
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developed into clinical candidates. The method has seen many improvements in the area of 
protein production and crystallisation, as well as the degree of automation associated with 
crystal manipulation (Nienaber et al., 2000). This method consists of soaking a crystal of the 
target protein with a cocktail of fragments, for a period of time between one to twenty-four 
hours. The solubility of the fragments and the stability of the protein must be verified in the 
soaking solution. After soaking, the X-ray structure is obtained and compared with the 
structure of the original protein. Hits can be identified by looking at the differences between 
the electron density maps (Bosch et al., 2006). One of the limitations of X-ray crystallography 
is that it is time-consuming compared to other technologies, but the main limitation is that the 
target protein must form suitable crystals for X-ray analysis, which makes it impossible for 
some proteins of interest to be studied using this technique (Bartoli et al., 2006). Once the 
fragments are found, their binding mode to the protein can be visualised immediately, which is 
the main advantage of X-ray crystallography. This information can then be used as a guide in 
the optimisation stage of the fragment following the approaches described before (Howard et 
al., 2006).  
 
1.8.2. Surface plasmon resonance (SPR)  
SPR is a powerful technique in studying biomolecular interactions in a highly sensitive and 
label-free detection format. It is also a versatile tool that provides kinetic information as well as 
affinity data (Neumann et al., 2007). In this technique the interactions between molecules are 
26 studied by measuring the variations in the refractive index between two phases separated by 
a thin metal film (usually gold or silver), called “sensor” (Bartoli et al., 2006; Neumann et al., 
2007). Collective oscillations of electrons at the metal surface (sensor) known as surface 
plasmons (SPs) can be seen as electromagnetic waves that propagate along the interfacial plane 
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between materials with negative and positive permittivities such as a metal-dielectric layer 
(Neumann et al., 2007; Daghestani and Day, 2010). The SPR phenomenon occurs when SPs 
are resonantly excited by coupling polarised light to the sensor to which target molecules are 
immobilised and addressed by ligands in a mobile phase (Rees et al., 2004; Neumann et al., 
2007; Daghestani and Day, 2010).The light’s wave vector component parallel to the metal 
surface needs to match that of the SPs, for this phenomenon to happen. The resonance 
condition is only satisfied at distinct angles of incidence, which appear as a drop in the 
reflectivity of incident light (Novotny and Hecht, 2006; Homola, 2003; Daghestani and Day, 
2010). Changes on the dielectric sensing surface, due to binding to the immobilised target for 
example, will cause a shift in the angle of reflectivity, followed by a detector, in order to satisfy 
the resonance condition, which forms the principle of SPR biosensing (figure 1.9) (Rees et al., 
2004; Neumann et al., 2007). 
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Figure 1.9: Diagram of a surface plasmon resonance biosensor (Kretchmann configuration). 
Light reflected from a prism induces an electromagnetic field which decays evanescently into   
both the metal and dielectric (biological) layer, with the field being greater in the dielectric 
medium due to increased damping in the metal, which is an effect that reduces the amplitude of 
oscillations in an oscillatory system (Daghestani and Day, 2010).  
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Figure 1.10: Detection of binding events during the SPR experiment. Changes in the angle of 
reflectivity that satisfies the resonance condition occur as the mobile analyte starts to flow over 
the sensing layer and bind to the immobilised substrate. These changes continue to occur until 
a level of saturation is reached and all binding sites are occupied. The angle of the detector 
returns back to baseline as the analyte completely dissociates from the substrate (Daghestani 
and Day, 2010). 
 
This binding experiment consists of two phases. In the first one, the soluble analyte (ligand) 
binds to the protein immobilised component, whereas in the second one the analyte dissociates 
upon rinsing with analyte free solution. The apparent rate constants for the association and 
dissociation phases of the reaction can then be calculated by fitting kinetics from these two 
phases to appropriate binding models. The apparent equilibrium constant is then deduced from 
the ratio of these values, describing the “binding affinity” (Neumann et al., 2007).  
Changes in the bound mass can be detected to a few picograms or less per square millimetre on 
the sensor surface. The experiment is carried in a continuous flow of running buffer. A 
sensorgram is a plot of response (measured in resonance units RU) against time, showing the 
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progress of the interaction (figure 1.11). The response may be absolute above a fixed zero point 
or relative to the response at another specified report point.  
 
Figure 1.11: Schematic illustration of a sensogram (Taken from the Sensor Surface 
Handbook).  
 
Although first demonstrated by Otto in 1968 (Otto, 1968), SPR was not made commercially 
available for biomolecular interaction applications until 1990 by Biacore® technology (GE 
Healthcare) (Owen, 1997). SPR studies are usually associated with this technology, which is 
routinely used to determine binding constants and kinetic measurements. However, the 
immobilisation of a target molecule onto the sensor chip surface has to be individually 
optimised for every system. There are three different approaches used to attach biomolecules to 
the surface of the sensor chip (figure 1.12). The first approach is the covalent immobilisation, 
where the molecule is attached to the surface through a covalent chemical link. The second 
approach is high affinity capture where the molecule of interest is non-covalently attached to 
another molecule. The latter is usually covalently immobilised on the chip surface.  
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Figure 1.12: The three different approaches used to attach biomolecules to the surface of a 
sensor chip (Taken from the Sensor Surface Handbook)  
 
There are two essential features of the sensor chip in BIAcore. The first one creates the 
conditions for generating an SPR signal and consists of a glass surface covered with a thin gold 
layer. The second one does not affect the SPR effect and varies between different types of 
chips. This feature of consists of a coating on the gold layer allowing the attachment of the 
target molecule and providing an environment where the interaction being studied will occur. 
There is a wide selection of different sensor surfaces offered by BIAcore. A common approach 
exploits the presence of the histidine (His) tag, routinely used in protein purification and in 
detection. The sensor chip is called NTA. It has a dextran surface matrix with immobilised 
nitrilotriacetic acid (NTA) for capture application. The NTA chelates metal ions such as Ni2+ 
leaving free coordination sites that can bind to polyhistidine tags on target proteins. The metal 
ion can be removed and his-tagged target released using EDTA to regenerate the surface 
(Nieba et al., 1997; the Sensor Surface Handbook)  
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1.8.3. Nuclear magnetic resonance spectroscopy (NMR)  
1.8.3.1. NMR in drug discovery  
NMR techniques can be incorporated into different stages of the drug discovery process. These 
stages, although may overlap, can be classified into hit finding, hit validation and hit 
optimisation. In general, the more advanced is the drug discovery process, the more complex 
are the NMR techniques needed. In hit finding, where the library size is relatively large, 1D 
ligand-based experiments such as Saturation Transfer Difference (STD), are most favourable 
because they allow high throughput as well as a reduced experimental time, and the time for 
sample preparation. Data analysis and interpretation are relatively easy and quick. 
Consequently, labelled samples, target-consuming and lengthy 2D/3D experiments are 
unfavourable at this early stage.  In hit validation, the library size is considerably reduced after 
the primary screen. At this stage, the aim is to exclude false positives arising from non-specific 
binding, changes in the pH, aggregation, and chemical reactions with the drug target. This can 
be achieved by using target-based NMR experiments such as chemical shift mapping. In hit 
optimisation the extracted true binders from the hit validation stage are assessed, ranked and 
clustered according to properties such as solubility, molecular weight, chemical accessibility, 
and affinities. The exact binding site (especially if more than one) and binding mode have to be 
identified.  In this phase, for example, ligands for different binding sites can be linked to 
achieve an increase in their binding affinity (Klages et al., 2007). 
 
1.8.3.2. General features  
A number of NMR screening experiments are based on the differences in NMR properties 
between small and large molecules. Depending on the residence time of the binding event, a 
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small ligand adopts the magnetic properties of the target to which it binds to. It is, therefore, a 
strict requirement for these experiments to distinguish between the ligands (library compounds) 
and the target (protein, DNA or RNA). This distinction can be achieved through two main 
methods. The first one is based on the difference in molecular masses between target and 
ligands where the latter needs to be considerably smaller than the target. A number of NMR 
parameters depend on the molecule’s rotational and translational diffusion rates which are 
molecular mass dependent. One of the parameters that depend on the rotational diffusion rate is 
the transverse relaxation of the NMR signal, where rapidly tumbling ligands relax at a slower 
rate than the large, slowly tumbling target.  Ligands can be distinguished from the target by 
their narrow lines, given that the linewidth is inversly related to the transverse relaxation rate. 
Added to this, comparably broad signals from the target can be minimized using suppression 
filters. Relaxation-related parameters also include the nuclear Overhauser effect (NOE) 
(homonuclear, 
1
H-
1
H), which is also rotational diffusion rate dependent.  Large molecules 
show a negative enhancement and small molecules show a positive one.  The use of relaxation- 
and /or diffusion-based filters involves the suppression of the ligand or target NMR signals, 
which places affinity limits on the techniques used (Klages et al., 2007; Jhoti et al., 2007). 
The second distinction approach is based on the much greater dispersion of chemical shifts 
observed for the target. This property of the target can be used to detect binding ligands by 
creating a non-equilibrium magnetization specifically on the target, which can be transferred to 
binding ligands. Taking this approach a step further ligands can be distinguished from target by 
creating a unique chemical shift range using specific isotope labelling of either the target or 
ligands. Thus, this method relies on the change in chemical environment caused by the binding 
ligand, which affects the chemical shifts of both target and ligand especially at the binding site. 
Distinction via isotope labelling avoids the use of filters, stated in the first method, to suppress 
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signals from the unwanted component, providing the techniques involved with wider affinity 
range.  
 
1.8.3.3. Ligand-based vs. target-based NMR spectroscopy  
There are two classes of NMR screening. The first one is the target detected method, where the 
effects of the binding ligand on the target NMR spectra are observed, whereas in the second 
one, the changes induced in the ligand NMR signals by binding to a large target are detected. 
Examples of the taget-based and ligand-based NMR experiments are shown in figures 1.13 and 
1.14, respectively.  
 Because the ligand and the target interact in aqueous solution, the ligands have to be soluble in 
water to prevent their aggregation effect that may lead to a false positive in the screening 
process (Klages et al., 2007). The effective molecular mass is increased by compound (ligand) 
aggregation, which drives the effective overall rotational correlation time (τc) upward and 
amplifies the corresponding relaxation parameter. The increase in τc and the enhancement of 
the corresponding relaxation parameter is also a consequence of ligand binding to large 
receptor molecule, which explains the false positive effect arising from ligand aggregation 
(Lepre et al., 2004).  
In the ligand based methods, the required amount of target, usually unlabelled with unlimited 
molecular mass, is smaller in the range of 1-50 µM for a 0.5 mL solution. The approach is 
relatively fast making use of one-dimensional (1D) NMR spectra. Because the target signals 
need to be suppressed, ligands binding with high affinity may not be differentiated from the 
target, and thus suppressed as well, which results in false negatives. Therefore, this approach is 
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limited to low and medium binding affinities with dissociation constant, Kd, values ranging 
between 0.1 µM and 1 mM (Webb, 2006).  
On the other hand, false positives may result from non-specific binding. In the target based 
approach, however, not only ligands binding with an affinity higher than 0.1 µM are detectable, 
but the distinction between specific and non-specific binding is easier (Lepre et al., 2004). It is 
also possible to exclude effects caused by aggregation and changes in pH. More importantly, 
structural information on the ligand target complex can be extracted from the spectra. This 
approach, however, requires larger amounts of the protein target (0.1-1 mM). It is rather a time-
consuming process making use of two-dimensional (2D) spectra. Target proteins, usually 
isotope labelled, have a restricted size to a maximum molecular weight of 100kDa (Klages et 
al., 2007). Labelling depends on the molecular weight of the target because of the need to 
sequentially assign the proteins (Lepre et al., 2004). Large proteins may require 
13
C labelling 
whereas a uniform 
15
N labelling is sufficient for the small ones (Klages et al., 2007; Jhoti et al., 
2007).  
 
1.8.3.4. Chemical shift mapping  
This approach is one of the most commonly used protein-based NMR experiments. It is 
characterised by the use of the target’s chemical shifts perturbations to detect/confirm binding. 
When a binding event occurs, the displacement of peaks can be monitored on multidimensional 
spectra (Klages et al., 2007). This is commonly done in 
13
C and 
15
N HSQC (Heteronuclear 
single quantum correlation) spectra. HSQC shows the single bond correlation between the X-
1H pair. 
15
N-
1
H HSQC shows a particularly high sensitivity to small changes in protein ligand 
interactions (Krishnan, 2005). 
42 
 
A typical experiment to detect binding and identify the amino acids in the binding pocket is to 
acquire and compare 
15
N-
1
H HSQC spectra of probes in the absence and presence of ligands. 
This experiment requires that the protein is 
15
N labelled. A reference spectrum of the 
15
N 
labelled protein is obtained. Then samples containing one or more ligands are analysed. One of 
the limitations of this approach is that the identification of the binding ligand is not possible if 
the sample contains a mixture. In this case the binding component has to be identified by 
separation (Meyer and Peters, 2003).  
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Figure 1.13: Example of a target-based NMR binding experiment.  The 
15
N-HSQC spectra for 
FKBP (a protein that binds tightly the potent immunosuppressant FK506) were acquired in the 
absence (magenta contours) and presence (black contours) of compound (A). Supperimposition 
of both spectra shows significant chemical shifts changes are observed for labelled residues 
(Shuker et al., 1991). 
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Figure 1.14: Example of a ligand-based NMR binding experiment which involves the use of 
1
H line broadening to detect binding. Shown are 
1
H NOESY spectra of two compounds in a 
mixture in the absence (top trace) and presence (bottom trace) of the catalytic domain of p38 
MAP kinase. Broad protein resonances were attenuated using relaxation filter. Resonances 
from 2-phenoxybenzoic acid (top right structure) and nicotinic acid (top left structure) are 
marked with dashed and solid arrows, respectively. There are overlapping resonances from 
both compounds showing at the peak at 7.2 ppm. Line broadening, suppression of fine 
structure, and attenuation of ligand resonance peak height due to the relaxation filter in the 
bottom spectrum indicate 2-phenoxybenzoic acid binds to p38, while nicotinic acid does not 
(Peng et al., 2001). 
 
Ligand-based NMR screening experiments such as Saturation Transfer Difference (STD) and 
WaterLOGSY are further discussed in this thesis and examples are presented in Chapter Three.  
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Other biophysical fragment screening techniques include isothermal titration calorimetry, mass 
spectrometry, thermal electrophoresis, capillary electrophoresis and differential scanning 
fluorimetry. There is no single technique that is suitable for all targets or compounds, which 
often require multiple methods to be deployed (Murray et al., 2012). Differential scanning 
fluorimetry (DSF) is discussed in Section 2.1.  
 
1.9. Examples of drugs originating from FBDD 
Examples of cases where FBDD has been successfully applied to a particular target are 
cumulating. This approach is continuously yielding drugs that are currently in different stages 
of clinical trials and even on the market (Baker, 2013). In 2011, Vemurafenib was approved as 
drug for metastatic melanoma. It only took six years for this drug to be marketed after scientists 
at Plexxikon started searching for low-molecular-mass hits against kinases, in 2005.   
In December 2012, a drug identified by Merk, known as MK-8931, entered Phase II/III clinical 
trials for Alzheimer's disease, which is a disease area in which there have recently been big 
deceptions in late-stage clinical trials. MK-8931, an inhibitor of the protease β-secretase 1 
(BACE1), derived from a small molecule which made interactions of only micromolar range 
affinity with the enzyme’s shallow binding pocket. This shallow pocket is one of the reasons 
that makes this target a challenging one. The small molecule was then built up into a drug 
candidate using structural information to acquire the physicochemical properties required to 
cross the blood-brain barrier.  
Navitoclax, currently in phase II clinical trials for the treatment of leukaemia, is an inhibitor of 
B cell lymphoma 2 (BCL-2) family proteins. This drug originates from two fragments 
identified by Abbott who found a way to join them together, using NMR structural 
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information. Although a relatively bigger molecule, Navitoclax disrupts a protein–protein 
interactions which is a difficult category of targets. 
AT13387 is a drug currently in phase II clinical trials for gastrointestinal stromal tumours. The 
drug was identified by Astex starting from a 223 Da fragment with an affinity in the 
micromolar range for heat shock protein 90 (Hsp90). Subsequent structure based design which 
involved the synthesis of 169 compounds resulted in a final candidate with a million-fold boost 
in potency.  
Table 1.1 lists other examples of drugs which derived from low-molecular-mass, low-affinity 
molecules and were upsized into drug leads by applying the FBDD approach. This is unlike 
traditional HTS campaigns where millions of compounds are evaluated in biochemical assays 
and only those hits showing sufficient activity are optimised. For difficult targets such as 
BACE 1, it is believed that molecules derived from FBDD have better drug-like properties than 
those resulting from HTS.  
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Table 1.1: Examples of compounds currently in clinical trials originating from fragment based 
drug discovery (Baker, 2013). 
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1.9.1. The application of FBDD to Hsp90 protein 
FBDD was applied to the chaperone Heat shock protein 90 (Hsp90a) using a combination of 
NMR and high throughput X-ray crystallography (Murray et al., 2010). Molecular chaperones 
are involved in the conformational stability, maturation, and function of other substrate 
proteins called clients (Bukau et al., 2006). Many of Hsp90 “clients” are oncology targets that 
are heavily involved in cancer progression, which makes the inhibitors of this chaperone 
potential chemotherapeutic agents in cancer (Workman et al., 2007; Whitesell and Lindquist, 
2005). The Hsp90 function involves the turnover of ATP to ADP via an ATPase activity linked 
to the N-terminal domain of this protein (Pearl and Prodromou, 2006). The ATP binding site 
has been characterised crystallographically, and the binding modes of many of the Hsp90 
inhibitors have been identified (Pearl and Prodromou, 2006). It has been shown that this 
inhibition results in the down-regulation of Hsp90 client proteins and antiproliferative activity 
(Vilenchik et al., 2004).  
The fragment screening of 1600 compounds (Hartshorn et al., 2005) was performed against the 
N-terminal domain of Hsp90. The compounds were screened in cocktails using the ligand-
based NMR experiment WaterLOGSY (section 3.1.2). Cocktails containing fragments that 
show a medium to strong positive LOGSY signal were further assessed by conducting a 
competition binding experiment in the presence of low concentration ADP, which, under the 
screening conditions, binds weakly to the ATPase domain to Hsp90 (Murray et al., 2010). A 
reduction in the ADP LOGSY signal indicates its displacement by the fragments present in a 
particular cocktail, which allows the identification of those fragments as binders to the 
nucleotide site of the target.  A second competition binding experiment was carried out to 
obtain further information on the affinity of the fragment at this site. The binding affinity of 
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ADP was increased by adding 5 mM Mg
2+
 to the screening solution, which leads to the 
displacement of fragments that weakly bind to the nucleotide site (Murray et al., 2010). 
Analysis of the NMR data resulted in 125 compounds progressing into further screening by X-
ray crystallography, using both soaking and co-crystallisation experiments. Crystal structures 
were obtained from a total of 26 of these fragments. The chemical structures for four of the 
validated hits are shown in figure 1.15. Isothermal titration calorimetry was used to determine 
dissociation constants to describe all binding affinities in this example (Murray et al., 2010).  
 
Figure 1.15: Structures for four validated hits identified by fragment screening against Hsp90. 
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Figure 1.16: Binding mode of aminopyrimidine fragments in Hsp90. (a) The crystal structure 
of Hsp90 with compound 1. The bond connecting the pyridine to the pyrimidine is heavily 
twisted. (b) The crystallographic overlays of compound 1 and ADP show that the interactions 
with Hsp90 are of a conserved nature. (c) Complex structure of compound 1 and Hsp90 
showing that the proximal lipophilic pocket on the middle-right-hand side of the protein 
surface is poorly filled by ligand surface (cyan) and is not occupied by water molecules. (d) F
o
 
− F
c
 electron density map contoured at 4σ for compound 2.  
 
1.9.1.1 Optimisation of aminopyrimidines starting from fragment 1 
There are two issues associated with the binding mode for compound 1 shown in figure 1.16a. 
The first one is that the fragment is twisted about the bond between the two aromatic rings, 
which is not the optimal geometry in the absence of the protein for such ring systems, so the 
51 
 
binding affinity could be improved through the stabilisation of the protein-bound conformation. 
The second one is that the proximal lipophilic pocket that is formed by the lipophilic side 
chains of Met98, Leu107, Phe138, Val150, and Val186 (figure 1.16c) is poorly filled by the 
fragment which explains the need to improve the hydrophobic fit in this region (Murray et al., 
2010). 
The first step in the optimisation of fragment 1 was the virtual screening of close analogues, 
which lead to the purchase of the simple chloro analogue, compound 5. The latter showed a 
100-fold improvement in affinity. The next step involved the synthesis of analogues of 
compound 5 by substitution with small groups at positions 2 and/or 6 of the upper phenyl ring 
with the aim of stabilising the twist observed in the X-ray structure and filling the proximal 
lipophilic pocket. The synthesis resulted in analogues 6, 7, 8 and 9, with compound 9 being the 
most ligand efficient molecule. Thus, the next iteration was based on compound 9 where 
further substitutions of the upper phenyl ring with small groups at positions 4 and/or 5 took 
place, with the aim of facilitating more lipophilic interactions with the enzyme and allow the 
introduction of solubilising groups to improve cell activity. This process resulted in compound 
14 which could be a potential lead molecule against Hsp90 (figure 1.17) (Murray et al., 2010). 
Tables 1 and 2 give data and chemical structures for the aminopyrimidines covered in this 
section. The tables give dissociation constants obtained with isothermal titration calorimetry, 
and the cell IC50 values reflect the inhibition of HCT116 cell proliferation.  
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Table 1.2: Potency of the aminopyrimidines enhanced by substitution with small groups at R2 
and R6. 
 
Table 1.3: Further substitutions of the upper phenyl ring with small groups at R4 and R5. 
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Figure 1.17: Crystallographic superimposition of compound 14 (in cyan) with the original 
compound 1 (in orange) from which it has derived. The original binding mode of the fragment 
is conserved in the final complex (Murray et al., 2010). 
 
1.9.1.2. Optimization of phenols starting from fragment 3 
The binding mode of the phenol compound 3 is described in figure 1.18. The first steps in the 
optimisation of fragment 3 involved the synthesis of the Chloro (15), ethyl (16), isopropyl (17), 
and tert-butyl (18) analogues, with compound 18 and 17 showing 100-fold improvment in 
potency (table 1.4).  
Given that the additional 2-OH group in the natural compound radicicol, which binds Hsp90, 
forms a direct hydrogen bond to Asp93, it was investigated whether a 4-OH phenol based on 
this substitution (2-OH) would have a greater affinity (figure 1.18b). The 2-OH substituted 
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compounds 19 and 20 were synthesised, but resulted in an approximately 10-fold decrease in 
potency compared to the corresponding 4-OH substituted compounds (table 1.4). 
The next synthetic iteration investigated a selection of amides to replace the diethylamide in 
compound 18. The X-ray structure indicated the importance of the carbonyl group which forms 
a direct hydrogen bond with the side chain of Thr184 and a strong water-mediated hydrogen 
bond with Asp93 (figure 1.18a). The torsion between the carbonyl and phenyl ring is highly 
twisted, and the torsion is stabilised by the tertiary nature of the amide. The design therefore 
focused on tertiary amides. Compounds 21 to 26 were prepared, with 24 showing an increase in 
affinity of several-hundred-fold.  
The next change consisted combining the best amides from the previous step with the isopropyl 
group, which involved the synthesis of compounds 27, 28, and 29.  The change to the isopropyl 
group resulted in an enhanced affinity and also reduced lipophilicity.  
The last step was the conversion of the best phenols 27 and 28 into resorcinols 30 and 31 
respectively. The additional OH group at position 2 gave large improvement in affinity, with 
the isoindoline resorcinol 31 showing subnanomolar affinity, excellent ligand efficiency, and 
good cell activity. This final step was driven by the similarity between the natural product 
radicicol and the compounds described above starting from fragment 3. The crystallographic 
superimposition of Hsp90 and compound 31 complex with Hsp90 and compound 3 complex 
shows that the binding mode was preserved during the optimisation campaign. 
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Figure 1.18: Binding mode of phenol fragment 3 in Hsp90. (a) Compound 3 forms hydrogen 
bonds with two of the conserved water molecules at the bottom of the ATP binding site there is 
no direct hydrogen bond to Asp93. (b) Superimposition of compound 3 with the natural 
product radicicol showed that the additional hydroxyl group in radicicol makes a direct 
hydrogen bond with Asp93 and with a conserved water molecule which suggested that the 
conversion of the phenol compound (compound 3) to the corresponding resorcinol may allow 
similar interactions. (c) Similarily to compound 1 (figure 1.16c), the proximal lipophlic pocket 
is poorly occupied by compound 3 (figure 1.18c). The latter could be optimized by the 
replacement of the methoxy group by other substituents which properly fill the pocket         
(Murray et al., 2010). 
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Table 1.4: Optimisation of the phenol series (Murray et al., 2010). 
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Figure 1.19: (a) Structure for the original compound 3 together with the lead molecule 31. (b) 
Crystallographic superimposition of lead molecule 31 (in cyan) and fragment 3 (in orange) 
from which it was derived. The lead molecule is over one million times more potent than the 
fragment (Murray et al., 2010). 
 
The final lead in the two cases of fragment to lead campaigns described above i.e. the 
optimisation of aminopyrimidines starting from fragment 1 and the optimisation of phenols 
starting from fragment 3 has a molecular weight of approximately 300 Da which allows the 
optimisation of non-potency related properties without the risk of having the final clinical 
candidate lying outside the “druglike space”. This is mainly due to the groups added during the 
optimisation stage, which are considered to be the most efficient groups ever reported 
(Verdonk and Rees, 2008). 
In summary, two series of compounds starting from fragments have been developed as a result 
of the application of the fragment screening approach to Hsp90 and subsequent structure-based 
design. An aminopyrimidine and a resorcinol leads with nanomolar affinity and good ligand 
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efficiency have been identified. Woodhead et al. (2010) describe how the resorcinol lead was 
converted into a compound that is currently in clinical trials for the treatment of cancer. 
The overall physical properties of the molecule were modified with the aim of altering its 
distribution characteristics. Several compounds have been prepared to replace the isoinlidine 
ring system with a basic group, which exhibited high tumour levels and efficacy in a mouse 
cancer model, although still having high plasma clearance. The next step involved the synthesis 
of closely related basic analogues to the previous series, which were tested in a preclinical 
candidate selection phase. During this phase, key parameters were investigated such as 
predicted human dose, selectivity/off-target effects, solubility, stability, formulation, and 
synthesis. At the end of this process, compound 35 (figure 1.20) as the l-lactate salt was 
selected as a clinical candidate and is currently being tested in man for the treatment of cancer 
(Woodhead et al., 2010). 
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Figure 1.20: (a) Compound 35 structure. (b) Crystal structure for compound 35 and Hsp90 
complex. The key binding features are identical to those of lead compound 31 (Woodhead et 
al., 2010). 
 
This example illustrates three concepts important to FBDD. The first one is that the fragments 
are of low molecular weight with low binding affinities (>100 μM). Despite the latter, the 
fragments can offer attractive starting points for medicinal chemistry by forming high quality 
interactions, which illustrate a second key concept to FBDD.  The third concept is that of 
ligand efficiency (LE) (defined in equation 1.1), which can be used to determine the potency of 
hits during lead identification stage and decide whether an increase in molecular size is 
necessary and can be justified by significant gains in potency (Murray et al., 2010). 
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1.10. Aim of this study 
The first objective of this project is to develop a protocol to screen for compounds that bind to 
the P. aerguinosa RmlA protein, by applying a number of fragment-based primary screening 
techniques. Differential scanning fluorimetry, ligand-ligand based NMR experiments and a 
biological coupled enzyme assay are applied and evaluated. This protocol can then be used in 
the future to screen different libraries against known or unknown target proteins.  The second 
objective of this project is to solve the structure of PA1645 protein from P. aerguinosa. The 
protein is overexpressed, purified and crystallised. The structural information on this protein is 
expected to provide some evidence on its function. The work presented in this thesis will help 
identify new starting points to design new drugs to combat multi-drug resistant P. aerguinosa 
and MTB.  
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CHAPTER TWO 
 
 
The application of Differential Scanning Fluorimetry (DSF) to detect ligands that bind 
and stabilise RmlA protein 
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The aim of this chapter is to evaluate the application of differential scanning fluorimetry (DSF) 
approach to detect ligands that bind and stabilize RmlA protein. The thermal unfolding of 
RmlA was monitored in the presence and absence of 500 compounds individually. The 
experiment was performed using a real-time PCR instrument in the presence of the fluorescent 
dye SYPRO orange. The opening section discusses the theoretical background of the DSF 
approach with an overview of the key advantages of the technique and where it stands 
compared to other fragment screening methods. It then describes the materials and method 
implemented to carry out the screening stage. That includes the overexpression and purification 
of the protein, a description of the library used and the experimental set up of the DSF 
approach. Next, it discusses the effect of the fragments tested on the protein’s stability. Finally 
the chapter concludes by reviewing the results obtained and looking into other ways of how to 
test those compounds further and alternative techniques that could be used to test the library. 
 
2.1 Introduction 
Protein thermal stability testing, also known as thermofluor (TF) or differential scanning 
fluorimetry (DSF) (Ericsson et al., 2006; Niesen et al., 2007) , is based on the measurement of 
the increase in the thermal stability of the protein induced by ligand binding. The approach 
consists of applying gradually increasing temperature on purified proteins, in the presence and 
absence of a ligand. The protein melting temperature is defined as (Tm), which is known as the 
midpoint of the protein unfolding position. The Tm value (the inflection point of the transition 
curve, figure 2.1), can be calculated using the following equation, derived from the Boltzman 
equation: 
     
       
     
(
    
 )
      (2.1) 
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where “LL” and “UL” are the values of minimum and maximum intensities, respectively, “a” 
denotes the slope of the curve within Tm , “y” and “x” denote the fluorescence intensity and the 
temperature, respectively (Vedadi et al., 2006; Cummings et al., 2006; Niesen et al, 2007).  
In the DSF approach an “environmentally sensitive” dye which specifically interacts with non-
native protein is used as an indicator to observe the amount of unfolded protein in solution as a 
function of temperature (Mezzasalma et al., 2007; Cummings et al., 2006). This is achieved by 
measuring the fluorescence from the dye which results from the changes in the dye’s emission 
properties upon interaction with unfolded protein (Vedadi et al., 2006). DSF uses a number of 
fluorescent dyes which differ in their optical properties. The dyes’ fluorescence is quenched in 
an aqueous solution, whereas in non-polar environment, such as the hydrophobic sites on 
unfolded proteins, the fluorescence intensity becomes significantly higher. With a high signal 
to noise ratio, SYPRO orange is currently the dye with most favourable properties for this 
approach. It has a relatively high wavelength for excitation (near 500 nm) which reduces the 
chances of any small molecule causing its fluorescence intensity to quench and therefore 
interfering with its optical properties (Niesen et al., 2007). The emission wavelength of 
SYPRO orange is near 600nm (Niesen et al., 2007). Some proteins may show no unfolding 
transition when analyzed using SYPRO orange, in which case an alternative dye should be 
tested. The molecular structure of SYPRO orange is not disclosed, (symbolized as a three-ring 
aromatic molecule in figure 2.1) (Niesen et al., 2007).  
Most ligands that bind specifically to the native protein will increase the Tm, and a temperature 
shift (∆Tm) between the protein’s melting temperatures in the two conditions is observed and 
measured. The extent of this shift is believed to be proportional to the ligand’s binding affinity 
for the protein (Cummings et al., 2006). Ligands that bind non-specifically are associated with 
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aggregation which destabilises the protein tertiary structure and do not test positively in DSF 
(Cummings et al., 2006).  
SYPRO orange Protein
Exposure of 
hydrophobic 
parts as protein 
unfolds
Gradual removal of 
protein from solution 
due to precipitation 
and aggregation
Strong  fluorescent light of 
610 nm emitted by the dye 
molecules bound to non-
polar parts
Excitation of a basic
fluorescence intensity 
by light of 492 nm
 
Figure 2.1: fluorescence intensity plotted as a function of temperature for the unfolding of 
protein (citrate synthase). The plot has a sigmoidal shape which is illustrated by a two-state 
transition depicted in this figure. The lower level (LL) and upper lever (UL) of the fluorescence 
intensity defined by equation 2.1 are also demonstrated here (figure taken and modified from  
Niesen et al, 2007). 
 
A key advantage of the DSF approach is its applicability to a wide range of proteins. In 
addition to this, it is a rapid and cost effective approach that requires relatively small amounts 
of protein and can be implemented in any laboratory (Vedadi et al., 2006). Furthermore, unlike 
other screening methods such as NMR, DSF sets no upper limit on the binding affinity that can 
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be measured. It is possible to screen for compounds with expected affinity (KD) between 1 nM 
and 1 mM. However, varying protein and compound concentrations is frequently necessary. 
For example, higher concentration may be required for compounds that bind with relatively 
low affinity, such as nucleotides. Also, it can be sometimes necessary to increase protein 
concentration to obtain an acceptable signal-to-noise ratio (Niesen et al, 2007). 
It also provides additional information on the ligand’s binding mechanism, making it possible 
to distinguish protein stabilizers from protein destabiliseers. Another main advantage of the 
approach is that it is applicable to different stages of the screening process, from primary 
screening to hit profiling. It is also a useful selection tool of protein constructs for use in 
screening and X-ray crystallography (Cummings et al., 2006). DSF also plays an important role 
in the expression and purification of proteins since it allows the detection of a specific ligand 
that improves the protein stability and hence decreases its potency to unfold and reduces the 
chances of its aggregation and susceptibility to proteolysis (Vedadi et al., 2006). 
The DSF approach has limitations that are known to make it difficult to calculate the Tm value. 
This may arise from a number of proteins not being folded in their native state and, therefore, 
have no hydrophobic core. On the other hand, some proteins can be thermo-resistant or have a 
thermal stability higher than the temperature range applied. Other proteins may have a 
hydrophobic core partly exposed in their native state. This results in a high initial fluorescence 
due to the dye interacting with the non-polar parts exposed. Only a small transitional increase 
in fluorescence may be observed due to the dye directly interacting with the compounds tested 
or ingredients in the solvents used. Finally, some transition curves observed are not 
monophasic which is due to the protein comprising more than one domain or forms oligomers 
(Niesen et al., 2007). 
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2.2. Materials and methods 
2.2.1. E. coli BL21 competent cells preparation 
Luria-Bertani (LB) Agar plates were streaked with BL21 E. coli cells (glycerol stock). The 
cells were grown overnight at 37 
o
C. After that, a single colony was placed in 10 ml LB media 
and left to grow overnight at 37 
o
C with shaking. One ml of overnight culture was used to 
inoculate 100 ml LB (1/100 volume) in 500 ml flask. The flask was incubated at 37 C (250 
rpm),   with shaking for two hours until OD600 approximately reached 0.4. The rest of the 
overnight culture was stored as glycerol stock (50 % v/v glycerol) at - 80 C until required.   
The cells were transferred into two pre-chilled centrifuge tubes (50 ml), and placed to chill on 
ice for 30 minutes. Cells were then centrifuged at 2800 rpm, for five minutes, at 4 C. Each 
pellet was resuspended in 12.5 ml 100 mM calcium chloride and 12.5 ml 40 mM magnesium 
sulfate (both pre-chilled on ice).  
The resuspended cells were left to chill on ice for a further 30 minutes before they were 
centrifuged again at 2800 rpm, for five minutes, at 4 C. After that, the resulting pellets were 
resuspended each in 2.5 ml 100 mM calcium chloride and 2.5 ml 40 mM magnesium sulfate. 
Pre-chilled autoclaved glycerol was added to 10% total volume. The cells were placed into 
small fractions (250 L aliquots) before they were frozen on dry ice and stored at – 80 C until 
usage.  
2.2.2. Genetic transformation of competent cells 
50 l of competent cells were first thawed on ice. After that, 1 l of RmlA plasmid was added 
to the cells. The cells were incubated on ice for 30 minutes before they were exposed to a 
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heatshock for 45 seconds at 42 C (waterbath). The cells were then incubated on ice for two 
minutes and transferred into an incubator at 37 C with shaking for one hour.  
Cells were then plated on selective media and grown overnight at 37 
o
C. The overnight culture 
was stored as glycerol stock (50 % v/v glycerol) at -80 C until required.   
The plasmid encoding for RmlA from P. aeruginosa contains a sequence coding for a 6 His-tag 
on the N-terminus of RmlA to allow an easy purification on metal-chelating columns. The 
amino acid sequence for the RmlA construct is as follows:  
 
HHHHHHGSMAMKRKGIILAGGSGTRLHPATLAISKQLLPVYDKPMIYYPLSTLMLAGI
REILIISTPQDTPRFQQLLGDGSNWGLDLQYAVQPSPDGLAQAFLIGESFIGNDLSALVL
GDNLYYGHDFHELLGSASQRQTGASVFAYHVLDPERYGVVEFDQGGKAISLEEKPLEP
KSNYAVTGLYFYDQQVVDIARDLKPSPRGELEITDVNRAYLERGQLSVEIMGRGYAW
LDTGTHDSLLEAGQFIATLENRQGLKVACPEEIAYRQKWIDAAQLEKLAAPLAKNGY
GQYLKRLLTETVY 
 
2.2.3. RmlA overexpression and purification  
In order to overexpress RmlA, E. coli BL21 competent cells transformed with the plasmid were 
grown at 37 C in LB medium containing 100 μg/ml ampicillin until the OD600 reached 0.6 ± 
0.8. Isopropyl-d-thiogalactoside (IPTG) was then added at 1 mM to induce the expression of 
the protein.  The cell culture grew for a further 4 hours before it was centrifuged at 6000 g for 
20 minutes at 4 C. Lysis buffer containing 20 mM Tris-HCl pH 8.5, 100 mM sodium chloride, 
100 μg/ml hen egg-white lysozyme, was used to resuspend the cell pellet. After 30 min 
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incubation at room temperature, Ethylenediaminetetraacetic acid (EDTA) free protease cocktail 
inhibitor tablet (Roche) and DNase I (20 μg/ml) were added.  The viscosity of the mixture was 
further decreased by sonication (seven cycles of one minute interrupted by one minute period 
on ice). The resulting lysate was centrifuged at 20,000 g for 20 minutes at 4 C to remove 
particulate matter.  
The supernant was collected and applied, using a syringe, to a 5 ml HiTrapTM FF column (GE 
Healthcare) pre-loaded with 0.1 M nickel sulfate and pre-equilibrated with buffer (20 mM Tris-
HCl, pH 8.0, 500 mM sodium chloride). 
The column was washed firstly with 20 column volumes of buffer containing 10 mM imidazole 
and followed by 30 column volumes of buffer containing 30 mM imidazole to remove non-
specifically bound, histidine-rich proteins. RmlA protein was eluted with 15 column volumes 
of buffer containing 500 mM imidazole. Purity was assessed by SDS-PAGE (figure 2.2).  
The purified RmlA was dialysed for 2 hours against 2 L of 50 mM Tris-HCl, pH 7.5, 10 mM 
EDTA, and then overnight against 2 L of 50 mM Tris-HCl, pH 7.5. Dialysed, purified protein 
was then concentrated to 11 mg/ml for crystallisation. 
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Lysate Molecular Weight 
Marker (kDa)
14.4
20.1
30.0
43.0
67.0
94.0
Elution fractions  (2-13) from Ni column
purification of RmlA 
1     2        3         4       5       6       7       8       9      10     11   12      13     14  
Figure 2.2: SDS-PAGE gel showing the elution fractions of RmlA during the purification 
stage. The protein appeared to be pure as judged by the gel. A single band at an apparent 
molecular weight of 34 kDa is observed (the calculated molecular weight of RmlA based on 
the protein’s sequence is 33,773 Da).  
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Figure 2.3: The gel filtration profile shows two peaks. The large symmetrical and sharp peak 
was verified as RmlA by mass spectrometry. This column was not calibrated. However, since 
RmlA from P. aeruginosa was known to be a tetramer (Blankenfeldt et al., 2000a; 
Blankenfeldt et al., 2000b) and in this project crystallised as a tetramer it was assumed this 
peak corresponds to a tetramer
1
.  
 
                                                 
1
 A subsequent purification by Magnus Alphey in the lab after I finished my thesis re-confirmed the protein elutes 
from gel filtration with a retention time consistent with a tetramer. 
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2.2.4. The identification of the protein by Mass Spectrometry 
The identity of the protein was confirmed by mass spectrometry following the in-gel digestion 
protocol. A band corresponding to RmlA was excised from the SDS-PAGE gel (figure 2.2) 
stained with Coomassie blue. The excision was as close to the boundary of the stain as 
possible, in a way as to minimise keratin contamination. The sample was submitted to the 
Mass Spectrometry and Proteomics Facility at the University of St Andrews, where it was 
reduced, alkylated and digested using the Genomic Solutions ProGest protein digestion station. 
Both MS and MSMS analyses were provided by the AB Sciex MALDI-TOF instrument. The 
sample was then processed using MASCOT, whereby mass spectra were matched against the 
NCBI database.  
Analysis of the gel sample resulted in an unequivocal definition of the protein as RmlA, with a 
sequence coverage of 70%  and a high score match of 1140 to Q9HU22 ( Glucose-1-phosphate 
thymidylyltransferase – P. aeruginosa ). Matched peptides are shown in bold red below.  
 
     1 MKRKGIILAG GSGTRLHPAT LAISKQLLPV YDKPMIYYPL STLMLAGIRE  
    51 ILIISTPQDT PRFQQLLGDG SNWGLDLQYA VQPSPDGLAQ AFLIGESFIG  
   101 NDLSALVLGD NLYYGHDFHE LLGSASQRQT GASVFAYHVL DPERYGVVEF  
   151 DQGGKAISLE EKPLEPKSNY AVTGLYFYDQ QVVDIARDLK PSPRGELEIT  
   201 DVNRAYLERG QLSVEIMGRG YAWLDTGTHD SLLEAGQFIA TLENRQGLKV  
   251 ACPEEIAYRQ KWIDAAQLEK LAAPLAKNGY GQYLKRLLTE TVY 
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Figure 2.4:  RmlA  MS spectrum showing that most peaks (red) match to that of the RmlA 
protein.  
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2.2.5. Fragment library 
A 500 compound fragment library at 25 micromole each, in 96-loose well Matrix plates was 
purchased from Maybridge. The powder compounds were dissolved in the appropriate volume 
of DMSO to give stock solutions equal concentrations of 150 mM.  
This fragment library is “Rule of 3” compliant. In this rule, as proposed by Astex Therapeutics, 
molecular weight is < 300 Da, ClogP ≤ 3, H-bond donors < 3, hydrogen bond acceptors  < 3, 
NROT < 3, and a total polar surface area  TPSA < 60 Å
2
 (Goddette, 2006). This “Rule of 
Three” could be a useful selection tool when building fragment libraries for efficient lead 
discovery (Congreve et al., 2003a). The fragments are quantifiably diverse through the 
application of industry standard chemometrics. They are also pharmocophorically rich with the 
inclusion of many unique Maybridge heterocycles. The purity of the fragments is high, 
exceeding 95%, with an assured aqueous solubility (ALogGPS – with outliers confirmed by 
actual solubility measurement). See list of compounds in Appendix A.  
 
2.2.6. DSF experimental setup  
The thermal unfolding of RmlA protein was monitored using the DSF approach, in the 
presence of the fluorescent dye SYPRO orange (Invitrogen), which has most favourable 
properties for DSF. The experiment was performed by using a real-time PCR instrument 
Stratagene Mx3005p. Protein-ligand solutions were dispensed into the wells of a 96-well thin 
wall PCR plate (Stratagene). Each well contained 5 µM (5 µl of 50 µM) protein, 2.5 × (5 µl of 
25 ×) SYPRO orange, 1.5 mM (0.5 µl of 150 mM ) library compound (ligand). A final well 
volume of 50 µl was filled up by the protein’s buffer.  In each plate there were 8 reference 
wells that did not contain any ligand. The experiment for each compound was repeated twice in 
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the same plate (figure 2.5). Since the compounds were in 100% DMSO, the corresponding 
volume of DMSO 0.5 µl was added to the reference wells for accurate comparison. The plates 
were sealed with optical quality sealing tape (Bio-Rad). Fluorescence changes in the wells of 
the plate were monitored simultaneously with a charge-coupled device (CCD) camera. The 
plate was heated up to 99 °C in increments of 0.5 °C.  
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  1 2 3 4 5 6 7 8 9 10 11 12 
A 3.A1 3.A1 3.A2 3.A2 3.A3 3.A3 3.A4 3.A4 3.A5  3.A5  3.A6 3.A6 
B 3.B1  3.B1 3.B2 3.B2 3.B3 3.B3 3.B4 3.B4 3.B5 3.B5 3.B6 3.B6 
C 3.C1  3.C1 3.C2 3.C2 3.C3 3.C3 3.C4 3.C4 3.C5 3.C5  3.C6 3.C6 
D 3.D1 3.D1 3.D2 3.D2 3.D3 3.D3 3.D4 3.D4 3.D5 3.D5  3.D6 3.D6 
E 3.E1 3.E1 3.E2 3.E2 3.E3 3.E3 3.E4 3.E4 3.E5 3.E5 reference reference 
F 3.F1 3.F1 3.F2 3.F2 3.F3 3.F3 3.F4 3.F4 3.F5 3.F5 reference reference 
G 3.G1 3.G1 3.G2 3.G2 3.G3 3.G3 3.G4 3.G4 3.G5 3.G5 reference reference 
H 3.H1 3.H1 3.H2 3.H2 3.H3 3.H3 3.H4 3.H4 3.H5 3.H5 reference reference 
Figure 2.5: Diagram illustrating the 96-well thin wall PCR plate setup. In each plate there are 
eight reference wells (coloured in purple). The rest of the wells illustrate the way the 
compounds from the first half of the 96-well library “plate 3” (as purchased) were laid out in 
the 96-well thin wall PCR plate (the experimental plate). As shown in the diagram each 
compound was tested twice within the same experimental plate. For example compound in 
position A1 in plate 3 of the library “3.A1” was dispensed into wells A1 and A2 into the 
experimental plate.  
 
2.2.7. Analysis of thermal shift data 
For each well solution, the temperature midpoint for the protein unfolding transition, Tm, was 
determined. The fluorescence intensity is plotted as a function of temperature. This generates a 
sigmoidal curve that can be described by a two-state transition (figure 2.1). The inflection point 
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of the transition curve (Tm) is calculated using equation (2.1). The statistical software 
Graphpad was used to perform a curve fitting to equation 2.1.For compounds with a sigmoidal 
fluorescence intensity curve, only their intensity observations lying between LL and UL were 
used to perform the curve fitting. Compounds which do not have a measurable peak are 
excluded (example figure 2.11). Graphdad then calculates the resulting Tm from fitting the data 
to equation 2.1. 
For ease of comparison of thermal shift between wells, graphs are normalized whereby the 
scale of the amplitude of each curve is between 0 and 1. This is accomplished in two steps. 
First, the fluorescence graph is translated downwards such that the fluorescence starts from 0. 
This is done by subtracting the minimum fluorescence (LL) of the compound’s fluorescence 
intensity observations from the DSF observations (FT) which occur at each temperature (T) 
interval. This will result in a new series of observations (NFT) where NFT = FT – LL. Second, 
the scale used to show the intensity of fluorescence is converted to values between 0 and 1 
which for graphical purposes would allow a better visual comparison of graphs. This is done by 
dividing each NFT by the maximum fluorescence (UL
*
) in the new data series observations 
NFT. The resulting transformed fluorescence intensity observations (RFT) will each have a 
value of     
     
   
. 
 
2.2.8. The application of DSF to other P. aeruginosa Proteins 
The thermal unfolding of another six P. aeruginosa proteins namely: PA4511, PA4715, 
PA4098, PA3333, Pqsl and PA4631, was monitored in the presence and absence of the 
Maybridge library compounds (described in Section 2.2.5), using DSF approach as outlined in 
section 2.2.6. The overexpression and purification of these six proteins, amongst others, were 
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carried out as part of the EU-funded AEROPATH project which aims to identify novel targets 
in the opportunistic pathogen P.aeruginosa. The strategies used for target selection which is 
based on the available genome sequence and preliminary annotation of P. aeruginosa strain 
PAO1, and protein production are described in Moynie et al. (2013).  
The thermal shift data for these peoteins was analysed as discussed in section 2.2.7.  
 
2.3. Results and discussion 
2.3.1 Results and discussion of thermal shift data for RmlA protein 
The average Tm value in the eight reference wells (protein only) as calculated was 
approximately 46.67 °C. 
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Figure 2.6: Relative SYPRO orange fluorescence plotted as a function of temperature for the 
unfolding of RmlA in the presence of this protein only (reference), repeated eight times. The 
average Tm value across the eight references was 46.67 °C (standard deviation = 0.24).  
 
Based on their effects on the protein thermostability, the compounds tested can be classified 
into four groups consisting of protein stabilizers, destabilises, denaturants and those which 
show no effect on protein stability.  
The first group of compounds which is of the most interest, repeated twice, gave a positive 
thermal shift, indicating an increase in protein stability. This suggests that each of these 
compounds might have bound specifically to an RmlA binding site, increasing the protein 
structural order and reducing its conformational flexibility. In total, 21 out of the 500 
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compounds tested have shown a positive thermal shift ranging from +1.3 °C to as high as 12 
°C.  
The thermal denaturation profile of RmlA in the presence of each of those 21 compounds is 
plotted along with the graph of that of the reference (RmlA only). The extent of the thermal 
shift (∆Tm = Tm reference - Tm compound) is also stated as calculated in Graphpad.  
The DSF results for the 21 compounds testing positive are listed below in figure 2.7 in an 
ascending order of ∆ Tm value. The extent of the thermal shift is believed to be proportional to 
the ligand’s binding affinity for the protein (Cummings et al., 2006). 
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Figure 2.7: Relative SYPRO orange fluorescence plotted as a function of temperature for the 
unfolding of RmlA in the presence and absence of each the 21 compounds that show a positive 
thermal shift (right shift). Each graph belonging to the compound tested, always shown in red 
and purple, is plotted against the reference (protein only), always shown in blue and green, 
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within the same plate. Given that the data is shown on the normalized scale for better visual 
comparison, the exact ∆Tm value (as calculated in Graphpad) is indicated in one of the top 
corners of each figure.  
 
Figure 2.8: Assembly of 14 of the compounds that gave a positive ∆Tmin theDSF screening. 
Looking at the compounds in figure 2.7, overall 11 out of 21 of those compounds have an NH2 
group. In figure 2.8a, are grouped those compounds with a single benzene ring, 7 of which 
have an NH2 group. In figure 2.8b, are grouped four compounds with pyridine ring, which may 
be useful in binding in a similar fashion to the pyrimidine ring of thymine. Two of them have 
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an NH2 group. In figure 2.8c, are grouped two indole compounds. The rest of the compounds 
do not seem to follow any particular pattern.  
For the second group of compounds there was no apparent significant shift in Tm, indicating 
that those compounds had no effect on the protein’s thermal stability. This may suggest that 
none of these bound to the protein. An example of the thermal shift of this second group is 
shown in figure 2.9 below. 
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Figure 2.9: Relative SYPRO orange fluorescence plotted as a function of temperature for the 
unfolding of RmlA in the presence and absence of compound 1H-benzimidazol-2-ylmethanol. 
The graphs belonging to this compound, coloured in red and purple, are plotted against the 
reference (protein only), coloured in blue and green, within the same plate. 1H-benzimidazol-2-
ylmethanol resulted in no significant ΔTm value (+ 0.3 °C), suggesting that this compound had 
no effect on the protein’s thermal stability. The likely reason for this is that 1H-benzimidazol-
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2-ylmethanol and the other compounds with similar effect may have not been into contact with 
the protein and are therefore not selected as likely hits in the DSF screening stage.  
 
The third group of ligands gave a negative (ΔTm), indicating a decrease in protein thermal 
stability. This could be a sign of misfolding or might suggest that the protein structural changes 
were induced towards a more disordered conformation, destabilising the tertiary structure. 
Non-specific binding i.e. away from protein binding sites is usually associated with such effect 
(Cummings et al., 2006; Ericsson et al., 2006). Non-specific binders have no direct effect on 
receptor activity. They usually bind receptor surface regions, such as hydrophobic patches on 
the protein surface (Lepre et al., 2004). Many of non-specific binders have been found to be 
promiscuous and act as aggregates (McGovern et al., 2002). These aggregates were proposed 
to either adsorb or absorb proteins (McGovern and Shoichet, 2003). Thus, these compounds do 
not form classical inhibitor−enzyme complexes which promote proteins stability, and so result 
in an increase of Tm. They rather induce the protein towards a more disordered conformation, 
through their promiscuity and adsorption to hydrophobic patches on protein surfaces, and so 
destabilising the protein, which results in a decreased Tm. An example of the thermal shift of 
this third group is shown in figure 2.10 below. 
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Figure 2.10:Relative SYPRO orange fluorescence plotted as a function of temperature for the 
unfolding of RmlA in the presence and absence of compound 3-phenyl-1H-pyrazole that 
resulted in a negative thermal shift (left shift). The graphs belonging to this compound, 
coloured in red and purple are plotted against the reference (protein only), coloured in blue and 
green, within the same plate. The ΔTm value of this compound as calculated is – 7 °C which 
indicates a significant destabilising effect on the RmlA protein. 3-phenyl-1H-pyrazole and 
other compounds with similar destabilizing effect on RmlA were excluded from the screen as 
such an effect is highly likely to be associated with non-specific binding.  
 
The fourth group of compounds gave no measurable transition (no peak observed). This is an 
indication of the potential aggregation/complete denaturation of the protein or its possible 
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destabilization/ partial unfolding (Ericsson et al., 2006). An example of the thermal shift of this 
fourth group is shown in figure 2.11 below. 
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Figure 2.11: Relative SYPRO orange fluorescence plotted as a function of temperature for the 
unfolding of RmlA in the presence and absence of compound methyl 1H-indole-3-carboxylate. 
The graphs belonging to this compound, coloured in red and purple, are plotted against the 
reference (protein only), coloured in blue and green, within the same plate. The unfolding 
profile in the presence of this compound shows no detectable peak, with a high initial 
fluorescence value decreasing with temperature. The possible reason for this is that at the start 
of measurement, the protein was already partially unfolded or aggregated in the presence of 
this compound. 1H-indole-3-carboxylate and other compounds with similar destabilising effect 
on RmlA were also excluded from the screen as such an effect is highly likely to be associated 
with non-specific binding and does not aid or support further structural studies.  
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2.3.2. Results of thermal shift data for the six P.aeruginosa proteins 
Table 2.1 summarises the average Tm values for each protein as calculated and the number of 
compounds resulting in positive thermal shifts (hits). 
For PA4511, PA4715 and PA4098 the results were repeated twice for positive hits, whereas for 
PA3333, Pqsl and PA4631 the library was only screened once due to time constraints. Thermal 
shift graphs for all positive hits are reported in Appendix C.  
The remainder of this research is focussed on the study of RmlA only and the six additional 
proteins described in this section were the focus of other studies carried out within the research 
laboratory in which this study was carried out. 
Protein 
Average Tm value 
ofProtein (
o
C) 
No of Hits 
PA4511 47.5 18 
PA4715 54.4 42 
PA4098 43.0 14 
PA3333 37.8 19 
Pqsl 36.7 11 
PA4631 39.4 5 
Table 2.1. Average Tm values and number of positive hits for the six P.aeruginosa proteins. 
 
2.4. Conclusion 
This chapter has discussed the application of DSF as primary screening tool in order to identify 
potential hit binders to the RmlA protein. The thermal unfolding of RmlA protein was 
89 
 
monitored using in the presence of the fluorescent dye SYPRO orange, which has most 
favourable properties for DSF. In total 500 compounds have been tested. 21 of those 
compounds were shown to promote the protein’s stability, whereas the rest of the compounds 
in the library displayed different effects including destabilization of the protein or its complete 
denaturation or simply had no significant effect on RmlA’s thermal stability.  
Although the group of interest from DSF screening are the compounds resulting in a positive 
thermal shift, since they are the most likely to be associated with specific binding, the rest of 
the compounds would also provide a helpful piece of information in explaining and discussing 
the follow up experiments described in chapter three and four. 
A number of ligand-based NMR screening techniques are discussed in chapter three in order 
further explore and compare/confirm the results from DSF. A coupled enzyme assay was also 
conducted to test the effect of some of those positive DSF hits on the biological activity of 
RmlA. 
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CHAPTER THREE 
 
 
The application of ligand-based NMR screening techniques in order to find novel 
inhibitors for RmlA protein 
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This chapter describes the application of a number of ligand-based NMR experiments to detect 
binding of small molecules from the 500 Maybridge library to the RmlA protein. The whole 
library was screened by running STD and WaterLOGSY experiments consecutively on the 
same sample. Then, compounds that gave positive results in both experiments were tested by a 
simple STD competition binding with dTTP, a natural RmlA substrate, in order to investigate 
their binding specificity. Section one of this chapter focuses on the theoretical background 
behind both WaterLOGSY and STD experiments with an overview of the advantages of each 
technique. The results are compared across the three experiments and contrasted against the 
results of the DSF screening. Finally the chapter concludes by reviewing the results obtained 
and looking into other ways of how to explore those compounds further and alternative 
techniques that could be used to test the library.  
 
3.1. Introduction 
3.1.1. Saturation transfer difference 
Saturation transfer difference (STD) is one of the most commonly used NMR-based screening 
experiments (Klages et al., 2007). As suggested by the name, STD takes the difference of two 
experiments (Krishnan, 2005). In the on-resonance experiment, selective saturation of the 
receptor proton magnetization is achieved by a train of frequency-selective pulses (Krishnan, 
2005). It is important to point out that the selected on-resonance irradiation frequency and 
ligand resonances must not overlap. The saturation propagates within the target protein, and 
eventually to the ligand via spin diffusion. This process is also known as intra or intermolecular 
1H-1H cross relaxation pathway (Lepre et al., 2004). The saturation is transferred to the ligand 
during its residence time in the receptor. The ligand then dissociates back into solution, where 
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the saturated state is retained in the free ligand due to their small spin- lattice relaxation rate 
constant. The number of saturated free ligands increases as the saturation energy continues to 
enter the system through the sustained application of the frequency selective pulses, showing as 
a reduced (destroyed) signal in the ligand NMR spectrum. Only the fractional reduction of the 
bound ligand resonances is shown in the difference spectrum (See figure 3.1). 
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Figure 3.1: Schematic representation of the difference spectroscopy in the STD experiment. 
Binding and nonbinding compounds are represented by circles and stars, respectively. (A) 
Represents the off-resonance (reference) experiment where irradiation is applied away from 
both receptor and compound resonances. The off-resonance experiment generates spectra with 
intensity I0. (B) In the on-resonance experiment, irradiation (rf-saturation) is applied to a 
frequency that contains only receptor resonances. In the event of binding, the irradiation 
propagates within the receptor and any binding compounds (depicted in red) resulting in a 
signal with decreased intensity ISAT. (C) Represents the STD difference spectrum ISTD = I0 - 
ISAT, which only yields the fractional reduction of the bound compounds resonances. Usually, 
receptor resonances are not visible because of the application of relaxation filters or the 
receptor present at low concentration. The intensity ISTD depends on the number of ligands 
receiving the saturation from the receptor. This number is defined as the average number of 
saturated ligands produced per receptor molecule (Lepre et al., 2004).  
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STD offers a number of advantages compared to target-based NMR techniques. First, the 
amount of the target and ligand required for reasonable results is reduced. It is easy to extend 
STD spectra, usually recorded as 1D spectra, to 2D or 3D versions where necessary (Klages et 
al., 2007). There is no upper size limit of the proteins. However, for the latter to be effectively 
saturated by spin diffusion, it should not be smaller than 10 kDa (Meyer and Peters, 2003). The 
technique can be applied to membrane proteins and immobilized targets (Klages et al., 2007; 
Krishnan, 2005). The difficulty in investigating membrane bound proteins is that they often 
lose their structure and functionality when devoid of their natural membrane environment. STD 
offers the great advantage of studying the binding to these proteins within their natural 
membrane environment without any complications whereas problems arise when using high 
resolution NMR spectroscopy (Meyer and Peters, 2003). Another advantage offered by STD 
NMR spectroscopy is that binding constants of ligands can be estimated. This can be achieved 
by performing a competition titration with a weaker ligand (Meyer and Peters, 2003). Results 
for binding constants obtained from SPR experiments gave comparable results to those 
obtained from STD (Meyer and Peters, 2003). However, high affinity binding ligands are not 
amenable to STD, which is the case with other ligand-based techniques (Klages et al., 2007). 
STD NMR is based on the transfer of saturation from the protein to the bound ligands, which 
are then moved into solution where this saturation is detected, due to the fast chemical 
exchange between their bound and unbound states of the ligands. However, for ligands that 
bind with high affinity, there is a slow chemical exchange between their bound and unbound 
state, which does not allow for the saturation to be effectively transferred further to the free 
state of the ligands. The STD effect is therefore not observed for high affinity binders, which 
show a false negative result (no ligand peaks are observed in the difference spectrum) (Webb, 
2006).  
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In addition to this, it is easy to conduct epitope mapping based on STD experiments. This is 
because the ligand moieties that are in direct contact with the receptor receive the highest 
degree of saturation, and can therefore be identified. STD-based epitope mapping can be 
further applied to allow the group epitope mapping (GEM). The ligand needs to have a fast off 
rate for the GEM to be observed. T2, the spin-spin relaxation time of the ligand in the unbound 
state has to be significantly longer than its residence time in the bound state (Mayer and Meyer, 
2001). 
 
3.1.2. WaterLOGSY 
Water-Ligand Observed via Gradient SpectroscopY (WaterLOGSY), is a highly sensitive 
ligand-based NMR screening method. Similar to STD, this technique depends on the excitation 
of the receptor ligand complex. This is, however, indirectly achieved by the selective 
perturbation of the bulk water magnetization, unlike the direct perturbation of receptor 
magnetization described in the STD experiment. The intended transfer of magnetization is 
therefore, water-receptor-ligand (figure 3.2) (Lepre et al., 2004). 
The idea behind this method generated from several experimental observations. Poornima and 
Dean (1995) studied protein-ligand complex X-ray crystallographic structures for the presence 
of water molecules at the protein/ligand interface. In all complexes water molecules were 
found at the ligand binding site. Most of those water molecules were found to be involved in 
bridging interactions by making three or more hydrogen bonds. These bonds connected ligand 
and protein with another water molecule in the site. Thus, these water molecules have a key 
role in the stabilization of the protein-ligand interactions (Dalvit et al., 2001).  
96 
 
The WaterLOGSY experiment involves the selective inversion of the water resonance. The 
most favored method to achieve this is the selective inversion via e-PHOGSY, where the water 
resonance is selectively inverted by 90° phase shifts of the selective 180° refocusing pulse 
(Dalvit et al., 2001). There are three simultaneous pathways through which the inverted water 
magnetization can be transferred to the bound ligands (figure 3.2). The first one involves direct 
1
H-
1
H cross-relaxation between the bound ligand and the long-lived “bound” water molecules 
within the binding pocket. The second pathway is direct cross-relaxation with labile receptor 
NH and OH protons within the binding site. The magnetization of these protons is inverted via 
chemical exchange with bulk water protons. This inversion is then propagate do the bound 
ligand by these NH/OH via intermolecular DD cross-relaxation. The third pathway involves 
indirect cross-relaxation with remote labile NH/OH protons via spin diffusion. The inverted 
magnetization is then transferred to other nonlabile spins via spin diffusion. These three 
magnetization transfer pathways allow binding compounds to pick up the bulk water inversion 
while residing in the receptor binding pocket (Lepre et al., 2004). 
  
97 
 
 
Figure 3.2: Schematic representation of the magnetization transfer mechanisms underlying 
WaterLOGSY. Hits and non-binders are represented by circles and stars, respectively. After the 
selective inversion of water resonance is achieved, ligands can receive magnetization from 
inverted bulk water via the long-lived water molecules within the ligand-binding site. Another 
way of magnetisation transferis through the exchangeable receptor protons within and remote 
from the binding pocket. The transfer of magnetization from inverted water to ligand protons in 
receptor-ligand complex (slow tumbling limit) is indicated in red. The red-blue shading 
indicates the free ligands (fast tumbling limit) receiving this magnetization. Only the binding 
compounds (hits) experience both ways of magnetization transfer. There is a buildup of the 
number of free ligands (red) that experience inversion transfer from bulk water as the ligands 
continues to exchange on and off the receptor (Dalvit et al., 2000; Dalvit et al., 2001).  
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In the WaterLOGSY experiment, the non-binding compounds have resonances that appear with 
opposite sign on the spectrum and tend to be weaker than those of the binding (interacting) 
ligands (figure 3.3). 
 
Figure 3.3: Example of one-dimensional WaterLOGSY spectrum for ligands E and F (200 
μM) in the presence of 10 μM cdk2 (cyclin dependent kinase 2) protein. cdk2 binders are 
identified by positive signals whereas non-interacting molecules can be identified by negative 
signals (Dalvit et al, 2001). 
 
3.1.3 Limitations to ligand-based NMR screening  
Ligand-based approaches are limited to low and medium binding affinities. As explained in 
section 3.1.1 ligands binding with high affinity may not be detected in the STD experiment, 
showing false negative results. On the other hand, false positives may result from non-specific 
binding. Non-specific binding can be a serious challenge facing ligand-based NMR screening 
techniques. It is important to differentiate between non-specific binding and low affinity 
99 
 
binding. Ligands with Kd values >10 µM and in fast exchange on the NMR time scale are 
considered to be low affinity binders. A non-specific binder can be a low affinity binder but the 
converse is not always true (Lepre et al., 2004). A low-affinity binder may specifically bind a 
well characterized site on the receptor, which regulates the receptor’s activity.The principle for 
specificity for these low-affinity binders is that they preferentially bind to the target’s active 
site, or a distinctly separate site proximal to the active site, for example through allosteric 
interactions. Low affinity binders can also specifically interact and modulate the receptor’s 
activity through linkage to a ligand bound to an active site. Non-specific binders, however, 
have no direct effect on receptor activity. They usually bind receptor surface regions, such as 
hydrophobic patches on the protein surface (Lepre et al., 2004). It is difficult for ligand-based 
approaches which make use of 1D NMR spectrum to distinguish between non-specific and low 
affinity binders. One preferred method is to conduct competition binding experiments to test 
for the displacement of low affinity specific binders upon addition of a known specific and 
competitive binder (Lepre et al., 2004). Another good approach would be the use of epitope 
mapping to obtain information on which parts of the ligand are involved in the binding 
interface (Mayer and Meyer, 2001).  
 The risk of non-specific binding can be reduced by working at lower receptor and ligand 
concentrations, as high ligand concentrations increase the chances of occupation of lower-
affinity non-specific binding sites as well as the likelihood of non-specific adsorption to 
hydrophobic patches on the protein surface (Murali et al., 1993). Added to this, working with 
full length proteins present fewer exposed hydrophobic patches than truncated domains, which 
decreases the likelihood non-specific adsorption to those patches. It is therefore worth 
considering alternative expressed forms of the target protein (Lepre et al., 2004). 
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3.2. Materials and methods 
The procedure to overexpress and purify RmlA is previously described in section 2.2 of 
Chapter 2. The same 500 fragment library (Maybridge compounds) used in the DSF screening 
was used here. The powder compounds were dissolved in the appropriate volume of DMSO to 
give stock solutions of equal concentrations of 150 mM.  
 
3.2.1. Cocktail preparation 
 In order to screen the whole library, compounds were grouped into cocktails. This allows 
saving experimental time and minimising the amount of protein required.  
An 1HNMR spectrum was recorded and checked for each fragment of the 500 library 
compounds. 53 compounds were excluded from the screen because of very little or no NMR 
signal available (the excluded compounds are highlighted in red in appendix A). The most 
likely reason for this is water solubility. The remaining 447 compounds were arrayed into 56 
cocktails of eight (with cocktail 56 containing seven compounds only) in a way such as there is 
minimum signal overlap (figure 3.4) for an example of how eight compounds are arrayed. 
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Figure 3.4: Example of cocktail 29 where 8 library compounds were arrayed together in a way 
such that for every compound there are a number of distinct peaks clearly visible for easy 
identification of the compound. This cocktail is composed of [5-(2-furyl)thien-2-
yl]methanol(light pink), 4H-thieno[3,2-b]pyrrole-5-carboxylic acid (blue), tetrahydropyran-2-
carboxylic acid ((red), (5-phenoxy-2-furyl)methanol(dark green), 2-piperazin-1-ylaniline 
(purple), 2,3-dihydrothieno[3,4-b][1,4]dioxin-5-ylmethanol (yellow), 3-(pyridin-2-
yloxy)aniline (light green), [4-(pyrrolidin-1-ylmethyl)phenyl]methanol (orange).  
 
3.2.2. Ligand-based NMR experimental set-up 
Both STD and WaterLOGSY experiments were carried out, consecutively, on the same sample. 
Each experiment lasts approximately 45 minutes. Therefore, the required time to run both 
experiments on each of the 56 samples was 90 minutes. A typical sample solution contained 20 
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µM RmlA protein , one cocktail of 8 compoundsat 1 mM final concentration each and 10% 
D2O. A total volume of 750 µl for each sample was filled up with phosphate buffer 50mM pH 
7.5, with a final DMSO concentration of 0.67 % v/v.  
Data for all NMR experiments were processed and analysed with the software TOPSPIN 3. 
Since both WaterLOGSY and STD were conducted on the same sample, they were processed 
consecutively for each compound to assess whether or not the ligand commonly tested positive 
or negative in both experiments.  
STD experiments were carried out using Bruker Avance 500 spectrometer with a 5mm inverse 
broadband tuneable (BBI) probe.
 1
HNMR spectra were acquired at 25 ºC, pH 7.5. In the on 
resonance experiment, irradiation is applied to a frequency that contains only the protein 
resonances (-0.25 ppm), whereas in the off resonance experiment, the irradiation is shifted to 
30 ppm, such that no NMR resonances are perturbed.  
The WaterLOGSY experiments experiment involves the selective perturbation of the bulk 
water magnetization applied to water resonance frequency (between 4.6 and 4.7 ppm).  
 
3.2.3. Binding specificity by STD competition experiment 
It was decided to reduce the number of positive results arising from non-specific binding. A 
simple STD competition binding experiment was conducted by adding deoxythymidine 
triphosphate (dTTP), a natural substrate for RmlA protein with Kd = 39 µM (Alphey et al., 
2013), to observe if any changes occur to the difference spectra of the compounds that gave 
positive results in both experiments ( STD and WaterLOGSY ). This is to investigate if the 
ligands are likely to be displaced by dTTP, should they bind to the same binding site as dTTP. 
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If no changes occur to the ligand’s difference spectrum in the presence of dTTP this would 
suggest that they are not competing for the same RmlA binding site. If, however, no difference 
spectrum is observed or a reduction in the intensity of the difference spectrum is detected , this 
would suggest that the ligand is totally or partially displaced by dTTP.  
Refer to figure 3.13 for the list of compounds tested. 
Sample solutions were prepared exactly the same way as in STD experiment. Each sample 
contained 20 µM RmlA protein, one cocktail of 8 compounds at 1 mM final concentration each 
( the ligand of interest for competition binding was added alongside the compounds belonging 
to the same cocktail) and 10% D2O. A total volume of 750Blankenfeldt µl for each sample 
was filled up with phosphate buffer 50 mM pH 7.5, with a final DMSO concentration of 0.67 
%. dTTP was added at 1 mM concentration to each sample.  
 
3.3. Results and data analysis 
3.3.1. STD results and data analysis 
In the STD experiment, the Off-resonance and On-resonance experiments are processed 
respectively for each cocktail. The difference spectrum between the two experiments is then 
calculated (as possible reduction in signal between off and on resonance experiments is not 
detectable by eye) and compared against each of the compound’s reference 
spectrumindividually. A positive STD result for each compound within a cocktail of 8 is 
described as the observation of a peak or peaks, in the difference spectrum, that corresponds to 
that of the compound in the reference spectrum recorded. See figures 3.5, 3.6.a, 3.6.b and 3.7 
for examples. 
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Analysis of the difference spectra of all STD experiments revealed both positive and negative 
results. In total 107 out of 447 ligands gave positive results.  
 
Figure 3.5: Example of compoundmethyl quinoline-6-carboxylate, one of the eight compounds 
which belong to cocktail 37,which gave a positive result in the STD experiment. The top 
spectrum is the 
1
HNMR reference spectrum of the compound (purple) which allows the 
identification of the peaks corresponding to the compound in the three STD spectra (on/off 
resonance and difference). This is because the STD spectra contain other peaks belonging to 
other compounds in cocktail 37 on which the STD experiment was run. The bottom (blue) 
spectrum represents the STD off-resonance experiment. The red spectrum represents the on-
resonance experiment. The difference between the two spectra On and Off resonance was 
calculated and presented as a difference spectrum (green), magnified. The difference spectrum 
shows peaks corresponding to that of methyl quinoline-6-carboxylate (distinct peaks belonging 
to this compound that can be observed in the difference spectrum are labelled in thick black 
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dots in both reference and difference spectra), which means that this compound tests positive in 
the STD experiment and is, therefore, a potential binder to the RmlA protein.  
 
 
Figure 3.6.a 
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Figure 3.6.b: Figures (a) and (b) represent an example of compound 4-isopropyl-3-
methylaniline hydrochloride, which also tests positive in the STD experiment. Similar to the 
previous example the compound’s 1HNMR reference spectrum is shown in purple, the off 
resonance in blue, the on resonance in red and the difference spectrum in green. The figure for 
this compound was split into two for clarity reasons as some of the peaks show in the region 
between 0-3ppm and others between 6 and 8 ppm. Similar examples are shown in appendix B. 
Distinct peaks belonging to this compound that can be observed in the difference spectrum are 
labelled in thick black dots in both reference and difference spectra in both figures 3.6.a and 
figure 3.6.b. 
 
Figure 3.7: Example of compound quinoline-6-carboxylic acid which tests negative in the 
STD experiment. All spectra are labelled similarly to the above two examples. The difference 
spectrum on this figure shows no peaks corresponding to the compound in the reference 
spectrum (purple). This suggests that this compound may not be a potential RmlA binder. 
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3.3.2. WaterLOGSY results and data analysis 
Analysis of the WaterLOGSY spectra is different from the case of the STD experiment. The 
distinction between a positive result (binding) and a negative one (non-binding) is based on the 
fact that non-binding compounds have resonances that appear with opposite sign on the 
spectrum and are weaker than those of the binding (interacting) ligands.LOGSY signals are 
positive for binders in the presence of a protein, and typically negative for free ligands in 
solution. In total, 107 out of the 447 compounds have shown a positive signal. 106 of those are 
the same compounds that gave a positive result in the STD experiment. See figures 3.8, 3.9 and 
3.10 for examples.  
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Figure 3.8: Example of compound methyl quinoline-6-carboxylate which tested positive in the 
WaterLOGSY experiment. The upper spectrum displays the ligand’s 1HNMR reference 
spectrum. The lower spectrum displays the WaterLOGSY spectrum of cocktail 37 which this 
compound belongs to. It is clear from the WaterLOGSY spectrum that signals belonging to 
methyl quinoline-6-carboxylate (labelled with thick black dots) appear positive, which suggests 
that this compound has a binding affinity to RmlA protein. This compound has also tested 
positive in the STD experiment (figure 3.5).  
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Figure 3.9: Example of compound 4-isopropyl-3-methylaniline hydrochloride which tested 
positive in the WaterLOGSY experiment. The upper spectrum displays the ligand’s 1HNMR 
reference spectrum. The lower spectrum displays the WaterLOGSY spectrum of cocktail 43 
which this compound belongs to. It is clear from the WaterLOGSY spectrum that signals 
belonging to 4-isopropyl-3-methylaniline hydrochloride appear positive, which suggests that 
this compound has a binding affinity to RmlA protein. Distinct positive peaks belonging to this 
compound are labelled with thick black dots in the reference and WaterLOGSY spectra. This 
compound has also tested positive in the STD experiment (figures 3.6.a and 3.6.b).  
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Figure 3.10: Example of compound quinoline-6-carboxylic acid which tested negative in the 
WaterLOGSY experiment. The upper spectrum displays the ligand’s 1HNMR reference 
spectrum. The lower spectrum displays the WaterLOGSY spectrum of cocktail 10 which this 
compound belongs to. It is clear from the WaterLOGSY spectrum that signals belonging to 4-
isopropyl-3-methylaniline hydrochloride appear negative, which suggests that this compound 
has no binding affinity to RmlA protein. Distinct negative signals belonging to this compound 
are labelled with thick black dots in the reference and WaterLOGSY spectra. This compound 
has also tested negative in the STD experiment (figure 3.7).  
 
In conclusion, in the case of the 447 compounds tried, STD and WaterLOGSY seem to agree in 
almost all cases with the exception of two compounds (figure 3.11 and figure 3.12). The 106 
compounds testing positive in both experiments are listed in figure 3.13. The spectra for these 
hit compounds are displayed individually in Appendix B where three spectra are shown in 
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total. From top to bottom, there is the ligand’s reference spectrum (green), the WaterLOGSY 
spectrum that corresponds to the cocktail the compounds belongs to (red), and only the 
difference spectrum of the STD experiment is shown (bleu).  
 
Figure 3.11: Compound [4-(1H-pyrazol-1-yl)phenyl]methanol which tested negative in the 
WaterLOGSY experiment. The bottom STD difference spectrum shows peaks matching to that 
of the compound, whereas LOGSY signals, the middle spectrum, are clearly negative. Peaks 
corresponding to this compound in all spectra are labelled in thick black dots.  
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Figure 3.12: Compound 6,7,8,9-tetrahydrodibenzo[b,d]furan-2-amine which tested negative in 
the STD experiment. The bottom STD difference does not significantly show peaks matching 
to that of the compound whereas LOGSY signals the middle spectrum are clearly positive. 
Distinct peaks belonging to this compound in all spectra are labelled in thick black dots.  
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Figure 3.13: The structures of the 106 compounds testing positive in both STD and WaterLOGSY 
experiments. With the exception of 4-hydroxy-1-methylbicyclo[2.2.2]octan-2-one, all compounds 
seem to enclose at least one aromatic ring in their structure.  
3.3.3. Results and discussion of the dTTP competition binding STD experiment 
First, STD experiments in the presence of dTTP were processed and the difference spectra 
calculated for each experiment. Then, for each ligand of interest the difference spectra in the 
presence and absence of dTTP were compared by superimposition.In 21 out of 106 of compounds 
there was a significant reduction in the difference spectrum intensity in the presence of dTTP. For 
the rest of compounds however no detectable change was observed. See figure 3.14 and 3.15 for 
examples.  
As previously described, in an STD experiment, a difference spectrum is an indication of a 
reduction in signal intensity in the event of binding. Therefore, if in the presence of dTTP no or 
significantly smaller reduction in signal intensity is observed, this may suggest that the ligand is 
competing on the same binding site as dTTP and was consequently totally/partially displaced from 
that binding site. Hence, a lower number of the ligands molecules are affected by saturation 
transfer, and a smaller reduction in signal is observed in the on-resonance experiment in the 
presence of dTTP.  
The results for the 21 compounds testing positive in dTTP competition binding STD experiment are 
listed in figure 3.16.  
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Figure 3.14: Example of compound 4-pyridin-3-ylaniline that tested positive in the STD 
competition binding experiment with dTTP. The upper spectrum represents the compound’s 
1
HNMR reference spectrum. The bottom two superimposed spectra display the STD difference 
spectrum in the absence of dTTP (blue) and in its presence (red). The peaks corresponding to this 
compound in the STD difference spectrum in the absence of dTTP (represented by thick black dots) 
are clearly, by superimposition,of a bigger intensity than those in its presence. This reduction in the 
sum of the difference, in the presence of dTTP,suggests that there is a smaller reduction in 
thecompound’s signal intensity in the presence of dTTP in the on-resonance experiment when 
irradiation is applied. There is therefore a possibility that the compound has been partially displaced 
by dTTP and both may have been competing on the same binding site.  
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Figure 3.15: Example of compound 5-(2-thienyl)tetrahydrothiophen-3-one where no difference 
spectrum was observed in the STD competition binding experiment in the presence of dTTP. This 
may suggest that the compound might have been totally displaced by dTTP and may well been 
competing for the same binding site.  
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Figure 3.16:dTTP competition binding STD experiment results for the 21 compounds that tested 
positive. The compounds ligand 
1
HNMR spectrum is depicted in green, the STD difference 
spectrum in the absence of dTTP is depicted in blue and the STD difference spectrum in the 
presence of dTTP is depicted in red.  
 
 
Figure 3.17: Assembly of the 21 compounds that tested positive in the dTTP competition binding 
STD experiment along with dTTP structure.  
 
Looking at the compounds in figure 3.17, overall the compounds do not seem to follow a single 
pattern. They have different substituents. Five of those compounds have an NH2 group, nine of 
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them have an OH group and four have a nitrile group. In figure 3.17a are grouped three compounds 
containing a thiophene ring. In figure 3.17 b are grouped those compounds with a single benzene 
ring, one of them having a sulphonamide group. In figure 3.17c are grouped three compounds 
containing two aromatic rings, one of them is a pyridine ring, which may be useful in binding in a 
similar fashion to the pyrimidine ring of thymine. In figure 3.17d are grouped five compounds 
containing each a six (benzene) and five membered aromatic rings. In figure 3.17e are grouped two 
amine compounds each containing a benzene ring fused with a five-membered aromatic ring 
comprising S or N atoms. In figure 3.17f is shown compound (4-methyl-4H-thieno[3,2-b]pyrrol-5-
yl)methanol which contains a thiophene ring fused with a pyrrol ring with an OH group substituent.  
  
3.4. Epitope mapping via STD 
It was noticed that the STD responses for compounds 2,3-dihydro-1,4-benzodioxin-2-ylmethanol 
and 5-(2-thienyl)tetrahydrothiophen-3-one were relatively stronger for the aromatic part, whereas 
no or very weaksignals in the difference spectrum corresponding to the aliphatic parts in these two 
compoundswere observed. The strong STD responses observed for the aromatic parts may be 
interpreted as closer contact between these parts of the ligand and receptor protons. This 
observation could be referred to as “epitope mapping” which provides a useful information about 
the orientation and the part of the ligand that is directly exposed to the protein binding site.  
The STD and WaterLOGSY results for 2,3-dihydro-1,4-benzodioxin-2-ylmethanol are shown in 
Figure 3.18. Along with these results is attached the structure of the compound labelled with the 
1
HNMR spectrum frequencies of the compound as predicted by ChemBiodraw software. The 
expected 
1
HNMR spectrum in this software is as predicted in chloroform, and may differ slightly in 
water and D2O. It is however a good guide to identify that part of the molecule to which the peaks 
in the 
1
HNMR spectrum correspond. As shown in this figure, LOGSY signals for the compound 
 128 
 
appear positive, whereas only the peaks corresponding to the aromatic ring of the compound show 
in the STD difference spectrum. No or very weak signals are observed in difference spectrum 
corresponding to the alicyclic ring and the small aliphatic tail of the short compound which may 
suggest that this part of the molecule is not as affected by the saturation transfer and hence may not 
be directly exposed to the binding site. 
 
Figure 3.18: STD and WaterLOGSY results for 2,3-dihydro-1,4-benzodioxin-2-ylmethanol 
 
Similarly to 2,3-dihydro-1,4-benzodioxin-2-ylmethanol results of STD and WaterLOGSY for 5-(2-
thienyl)tetrahydrothiophen-3-one are presented in Figures 3.19a and 3.19b. As shown in figure 
3.19a, the peaks corresponding to the thiophene ring are positive in the WaterLOGSY spectrum. 
These peaks also show in the STD difference spectrum. Whereas the peaks corresponding to the 
aliphatic part of the compounds, although appear positive in WaterLOGSY, do not show on the 
 129 
 
STD difference spectrum as observed in figure 3.19b.This may suggest that this part of the 
molecule is not as affected by the saturation transfer. 
 
Figure 3.19a: Positive STD and WaterLOGSY results for compound 5-(2-
thienyl)tetrahydrothiophen-3-one showing the peaks corresponding to the thiophene ring.  
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Figure 3.19b: STD and WaterLOGSY results for compound 5-(2-thienyl)tetrahydrothiophen-3-one 
showing the peaks corresponding to the thiolane ring.  
 
It was also noticed for the aliphatic compound 3-[(tetrahydrofuran-2ylmethyl)amino]propanenitrile 
that both WaterLOGSY and STD results appear negative for this compound. This compound was 
not selected as a positive hit. However it is a good example to support the assumption that aliphatic 
compounds or aliphatic parts in a compound are not particularity affected by the saturation transfer 
in the STD experiment (figure 3.20).  
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Figure 3.20: STD and WaterLOGSY results for 3-[(tetrahydrofuran-
2ylmethyl)amino]propanenitrile.  
 
3.5. Discussion and conclusion 
A 500 Maybridge Ro3 Library was screened for potential binders to RmlA protein, using ligand-
based NMR screening techniques. 53 compounds were excluded from the screen because of little or 
no NMR spectrum available. The remaining compounds were primarily screened by running STD 
and WaterLOGSY experiments. In total, 106 compounds out of the 447 tested gave positive results 
in both experiments, 21 of which seem to have been totally or partially displaced by dTTP in a 
dTTP competition binding STD experiment.  
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STD and WaterLOGSY seem to agree in almost all cases. It is therefore, worth considering running 
only WaterLOGSY for future screens for RmlA binders. Not only this technique is more sensitive 
but also generates straightforward results with no further processing required. 
With NMR beinga more sensitive technique mainly applicable to low and medium affinity binders, 
alarger number of compounds was detected in the NMR screening stage compared to DSF 
screening (106 Vs 23). However, it is important to note that 49 out of the 106 compounds which 
commonly tested positive in both STD and WaterLOGSY experiments were found to significantly 
destabilize the protein or cause its complete denaturation in the DSF screening discussed in chapter 
two. Such an effect is usually associated with non-specific binding. This suggests that there is a 
possibility that those compounds rather tested as false positives due to non-specific binding which is 
a known limitation of ligand-based NMR screening.  
On the other hand only 4 out of the 21 compounds that stabilize the protein in thermofluor have 
tested positive in STD and WaterLOGSY experiments. In this case the two approaches agree only 
to a certain extent. In figure 3.21 are grouped these four compounds. Three of them have an amine 
group and two of them have carboxylic acid group. One is an indole compound, the other has both 
aniline and pyridine rings, whereas the other two have a single benzene ring.  
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Figure 3.21: Compounds that tested positive in the STD and WaterLOGSY experiments and 
stabilise the protein in the DSF experiment.  
 
There remains a possibility that potential binders detected in the DSF screening are tight binders, 
because the technique lies no affinity limit and so allows the identification of such compounds. 
Such high affinity binders could have been missed in the ligand-based NMR screening, because 
their signals have been suppressed along with the target (relaxation filters), and therefore tested as 
false negatives.  
The magnitude of thermal shift in the DSF technique is believed to be proportional to the ligand’s 
binding affinity for the protein (Cummings et al., 2006). However, the extent of the thermal shift 
observed for different compounds with the same affinity at the relevant temperature is dependent on 
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the contributions of enthalpy and entropy of binding. More entropically driven compounds, such as 
hydrophobic compounds, result in larger ∆Tm values (Holdgate and Ward, 2005; Niesen et al., 
2007). Compounds with similar physicochemical properties can be ranked based on their ∆Tm 
(Holdgate and Ward, 2005; Niesen et al., 2007). 
NMR and DSF screening results can be considered as complementary because the ligands that are 
of interest at this stage are those that bind specifically and stabilise the protein.This is why, the 
compounds that tested positive in the dTTP competition binding STD experiment along with the 
DSF screening hits will be further explored by testing their potential inhibition of RmlA biological 
activity. This will be achieved by conducting a coupled enzyme assay described in chapter four.  
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CHAPTER FOUR 
 
The application of a coupled enzyme bioassay in order to detect compounds that inhibit the 
biological activity of RmlA 
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This chapter is reporting the test for compounds that inhibit the reaction catalysed by RmlA. The 
compounds tested here are those that gave positive results in the dTTP competition binding STD 
experiment and in the DSF screening. A coupled enzyme assay was used to monitor RmlA activity, 
following the generation of pyrophosphate, in the presence of those compounds. This assay, 
although not suitable to determine accurate kinetic values, is a good guide to rates of reaction. 
The opening section discusses the original work conducted by O’Brien (1976) which made this 
assay possible and its usefulness in monitoring RmlA activity.It then describes the materials and 
methods implemented to conduct the assay.Next, it discusses the effect of the fragments tested on 
RmlA’s catalytic reaction. Finally the chapter concludes by reviewing the results obtained from the 
three approaches applied in chapter two, three and four and looking into alternative and more 
advanced techniques that could be used to test those compounds further.  
 
4.1. Introduction 
RmlA is one of many pyrophosphate-generating enzymes which utilize nucleotide triphosphates in 
their catalytic biosynthetic reactions. RmlA (glucose-phosphate thymidylyltransferase), a 
homotetramer, is the first enzyme in the L-rhamnose pathway. It transfers thymidyl monophosphate 
nucleotide (TMP) to glucose-1-phosphate, forming dTDP-D-glucose. The latter is dehydrated to 
dTDP-6-deoxy-D-xylo-4-hexulose by RmlB (dTDP-D-glucose 4,6-dehydratase), the second 
enzyme in the pathway. 
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Figure 4.1: The reaction catalysed by RmlA indicating that the enzyme generates pyrophosphate as 
a product (Blankenfeldt et al., 2000b). 
  
O’Brien (1976) developed a rapid continuous spectrophotometric method for the assay of 
argininosuccinate synthase. The latter generates pyrophosphate as a product which is linked to 
NADH oxidation by a series of four coupling reactions. The usefulness of this assay was 
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demonstrated in the determination of the levels of activity of argininosuccinate synthetase in crude 
extracts of rat liver. This was following O'Brien’s interests in metabolic defects involving the 
enzymes of the ornithine cycle (Krebs-Henseleit urea cycle). In crude liver extracts: 
 
The isolation of a unique enzyme (which catalyses reaction 4.2),pyrophosphate:fructose-6-P 
phosphotransferase (   -PFK), a pyrophosphate-dependent phosphofructokinase, from 
Propionibacterirtm shermanii by O’Brien and coworkers, made this assay possible and provided a 
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mechanism by which the generation of pyrophosphate could be linked to NADH consumption 
(O’Brien et al. 1976).  
 
The methodology for utilizing this reaction in the assay of argininosuccinate synthetase and its use 
in other pyrophosphate-generating reactions is described in detail in O'Brien (1976). The procedure 
consists of converting one mole of fructose-6-phosphate to two moles of glycerol-3-phosphate for 
each mole of pyrophosphate produced, with the subsequent oxidation of two moles of NADH. The 
sequence of the reactions after reactions (4.1) and (4.2) is as follows:  
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Sum: 
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The coupling system described by O'Brien has an important potential usefor the assay of many 
other pyrophosphate-generating enzymes for which rapid spectrophotometric assays were not 
previously available. The availability of the PPi-dependent phosphofructokinase which must be 
prepared from P. shermanii is a requirement. It is easy to culture P. shermanii and isolate this 
enzyme which is stable for a period over one year when frozen. This assay was made commercially 
available (Sigma product number P7275). It was previously used to measure RmlA enzymatic 
activity according to the manufacturer instructions. This coupled assay is a good guide to rate of 
reaction, but it is not suitable to determine accurate kinetic values (Blankenfeldt et al., 2000a).  
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4.2. Materials and methods 
4.2.1. Protein overexpression and purification 
The procedure to overexpress and purify RmlA is previously described in section 2.2.  
 
4.2.2. Fragment library 
Only the compoundsthat tested positive in DSF screening stage (see figure 2.4) and in the dTTP 
competition binding NMR STD experiment (see figure 3.16) have been tested with the coupled 
enzyme assay.  
 
4.2.3. Assay description  
RmlA activity is detected following the enzyme’s generation of pyrophosphate. The latter is 
determined according to the coupled reactions described in figure 4.1 and reactions 4.2, 4.3, 4.4 and 
4.5 described in sections 4.1. The reaction is monitored spectrophotometrically at 340 nm.  
The pyrophosphate reagent is a lyophilised powder which contains coupling enzymes, buffers, salts 
and stabilisers. The contents of each vial of this reagent was dissolved in 4 ml of water. Table4.1 
summarises the concentration of each component after reconstitution.  
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Components Concentration 
PPi-PFK 0.5 units/ml 
Aldolase 7.5 units/ml 
GDH 5 units/ml 
TPI 50 units/ml 
Imidazole . HC1, pH 7.4 45 mM 
Citrate 5 mM 
EDTA 0.10 mM 
Bovine serum Albumin 5 mg/ml 
β-NADH 0.8 mM 
F-6-P 12 mM 
Mg++, Mn++, Co++ 2 mM, 0.2 mM, 0.02 mM 
Sugar Stabiliser 5mg/ml 
Table 4.1: A summary table of the concentrations of the pyrophosphate reagent after reconstitution.  
 
The activity of RmlA was monitored by following the rate of NAD
+
 production. The reduced form, 
NADH, has a strong absorbance at 340 nm, while NAD+ has practically no absorbance at 340 nm. 
The assays contained 333 µl of the pyrophosphate reagent (1/3 of the total volume as indicated in 
the product technical bulletin), 0.5 mM α-D-glucose-1-phosphate dipotassium salt hydrate (Sigma 
G6750), 0.5 mM dTTP, 7.5 nM RmlA enzyme and 0.5 mM of the compound tested. Each 
compound was added individually in excess (at high concentration 0.5 mM) because they are 
expected to be weak binders. 
Initially, prior to testing any compound, the assay was run at different protein concentrations (20 
µM, 10 µM, 5 µM, 2.5 µM, 250 nM, 62 nM, 7.5 nM, 3 nM).  
Reactions were carried out in 3 ml cuvettes (1 cm light path) at 30 °C. Absorbance was measured 
using a Varian 50 bio UV visible spectrophotometer.Temperature was controlled using a Varian 
PGB 150 water Peltier system.Prior to adding the enzyme, solutions were mixed by inversion and 
the initial A340 nm vs. water for each cuvettewas recorded. After that, the enzyme was added at 7.5 
nM and solutions were mixed again by inversion. The decrease in A340 nm was monitored for 10 
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minutes, at 30 °C for all cuvettes until no further decrease was observed and the final A340 nm for 
each cuvettes was recorded.  
The inhibition of RmlA was tested by the addition of TMP at different concentrations, as a control 
experiment. Assays contained 333 µl of the pyrophosphate reagent, 0.5 mM α-D-glucose-1-
phosphate dipotassium salt hydrate, 0.5 mM dTTP, 7.5 nM RmlA and TMP added at 500 µM, 100 
µM and 50 µM respectively.  
 
4.3. Results and discussion 
An RmlA concentration of 7.5 nM was chosen as a reference concentration, against which the 
observed rate of the catalytic reaction of the protein in the presence of each compound was 
compared. The reason for choosing this concentration is that it allows the reaction to terminate 
within the first 10 minutes as suggested by the product technical bulletin. Running the assay at 
different protein concentrations also demonstrates that RmlA is a rate-limiting enzyme (figure 4.2).  
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Figure 4.2: Absorbance against time graphs showing the effect of enzyme concentration on the rate 
of RmlA catalyticreaction.  
 
No decrease in absorbance is observed when TMP is added at 500 µM, suggesting a total inhibition 
of the activity. When TMP is added at 100 µM a partial inhibition is observed, whereas at 50 µM 
the rate of the reaction remains the same as the reference, suggesting no decrease in the enzyme’s 
activity. The inhibition of RmlA by TMP using this coupled enzyme assay, shown in figure 4.3, 
demonstrates that this assay is robust. 
 
 
 146 
 
 
Figure 4.3: Absorbance against time graphs showing the inhibition of RmlA catalytic reaction by 
TMP.  
 
Almost all of the compounds tested have shown no or very little inhibition of the enzyme activity, 
as the observed rate of the reaction was almost exactly the same as observed in the reference rate 
(enzyme only at 7.5 nM). The results from compounds that tested positive in the thermal shift assay 
are listed in figure 4.9, whereas figure 4.10 shows the assay results obtained from the compounds 
that tested positive in the dTTP competition binding NMR STD experiment.  
Only one compound from those tested so far, 3-pyridin-3-ylaniline, has shown significant inhibition 
of the enzyme activity. Figure 4.4 shows that when this compound is added at 0.5 mM 
concentration, only a very small decrease in absorbance is observed. The enzyme activity was 
assayed again in the presence of this compound at the same concentration to confirm the 
consistency of the result.The compound was then added at lower concentrations 100 µM and 50 
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µM, where a partial inhibition of RmlA activity was consistently observed. Overall, the graphs 
show a decreasing rate of the reaction with increasing compound concentration. 3-pyridin-3-
ylaniline comprises an aniline group and pyridine groups. The latter may bind in a similar fashion to 
the pyrimidine ring of thymine. 
3-pyridin-3-ylaniline had tested positive across STD, WaterLOGSY and DSF screening 
experiments. A summary of all fragment binding experiments for 3-pyridin-3-ylaniline (STD, 
WaterLOGSY and DSF) is shown in figures 4.4, 4.5 and 4.7. Figures 4.6 and 4.8 show a summary 
of STD, WaterLOGSY and DSF experiments for compound 4-pyridin-3-ylaniline. Although the 
latter has tested positive in the STD and WaterLOGSY experiments, it has shown a deacrease in the 
protein thermal stability in the DSF experiment. This may suggest that the position of the amino 
group in the aniline may play an important role in stabilising the protein in the event of binding.  
 
Figure 4.4: Absorbance against time graphs showing the inhibition of RmlA catalytic reaction by 
3-pyridin-3-ylaniline.  
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Figure 4.5: Positive STD and WaterLOGSY results for 3-pyridin-3-ylaniline. Distinct peaks 
belonging to this compound are labelled in thick black dots. On the WaterLOGSY spectrum (red) 
the compound’s peaks appear positive. The STD difference spectrum shows peaks corresponding to 
the compound. 
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Figure 4.6: Positive STD and WaterLOGSY results for 4-pyridin-3-ylaniline. Distinct peaks 
belonging to this compound are labelled in thick black dots. On the WaterLOGSY spectrum (red) 
the compound’s peaks appear positive. The STD difference spectrum shows peaks corresponding to 
the compound. 
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Figure 4.7: Relative SYPRO orange fluorescence plotted as a function of temperature for the 
unfolding of RmlA in the presence (red and purple graphs) and absence (blue and green graphs) of 
3-pyridin-3-ylaniline. The latter results in a positive thermal shift of 3.9 °C, indicating an increase 
in protein stability.  
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Figure 4.8: Relative SYPRO orange fluorescence plotted as a function of temperature for the 
unfolding of RmlA in the presence (red and purple graphs) and absence (blue and green graphs) of 
4-pyridin-3-ylaniline. The latter results in a negative thermal shift of -1.4 °C, indicating a decrease 
in protein stability.  
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Figure 4.9: Absorbance against time graphs from compounds that tested positive in the thermal 
shift assay. The graphs showing the rate of the catalytic reaction of the protein in the presence of 
each compound are depicted in red, whereas the two black curves show the rate of this reaction in 
the presence of the protein only (control).  
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Figure 4.10: Absorbance against time graphs from compounds that tested positive in the dTTP 
competition binding STD experiment. The graphs showing the rate of the catalytic reaction of the 
protein in the presence of each compound are depicted in red, whereas the two black curves show 
the rate of this reaction in the presence of the protein only (control).  
 
4.4. Conclusion and future work 
A coupled enzyme assay was used to monitor RmlA activity, following the generation of 
pyrophosphate, in the presence of compounds that gave positive results in the dTTP competition 
binding STD experiment along with the DSF screening hits. This assay is a guide to rates of 
reaction but it not suitable to determine accurate kinetic values (Blankenfeldt et al., 2000a). In 
summary only one compound, 3-pyridin-3-ylaniline, has shown significant inhibition of the enzyme 
 158 
 
activity. This compound has also tested positive across the techniques applied in this screening i.e. 
DSF, STD and WaterLOGSY. 
 The identified compounds from the DSF and NMR primary screening stage need to be further 
confirmed and validated using more advanced techniques. Crystallography studies remain the best 
tool to investigate these compounds further. This method consists of preparing complexes of 
enzyme and inhibitor by soaking or co-crystallisation of RmlA protein with a cocktail of fragments, 
for a period of time between one to twenty four hours. After that, the X-ray structure is obtained and 
compared with the structure of the original protein.Hits can be identified by looking at the 
differences between the electron density maps. Once the fragments are found, their binding mode to 
the protein can be visualised immediately, which is the main advantage of X-ray crystallography. 
This information can then be used as a guide in the optimisation stage of the fragment. 
Figure 4.11 is a summary diagram that provides an account with statistics of the methods 
implemented in chapter two, three and four in order to screen RmlA for fragment binding against a 
500 Maybridge Ro3 library.  
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Figure 4.11: Summary diagram of the protocol followed in screening RmlA for potential inhibitors 
against a 500 Maybridge Ro3 library.  
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CHAPTER FIVE 
 
 
Purification, crystallisation and structural characterisation of  
PA1645, a Pseudomonas aeruginosa protein 
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This chapter discusses the application of S-SAD (sulphur-single wavelength anomalous dispersion) 
phasing in order to determine the crystal structure of PA1645, a protein from P. aeruginosa. There 
is a need for more potential therapeutic targets in gram- negative bacteria. So called rational drug 
design is a recognised strategy for which a characterised structure is required. PA1645 was targeted 
because it is not found in humans and thought to be essential to bacteria. The overexpression, 
purification and the crystallisation of the protein is reported. The protein was found to be a novel 
fold for which function could not be determined.  
 
5.1 Introduction  
5.1.1. S-SAD phasing as a powerful tool in protein X-ray crystallography 
PA1645 structure was solved with the single wavelength anomalous dispersion technique which 
exploits the very weak anomalous signal of sulfur in the native protein crystal. The technique was 
first reported in 1981 by Hendrickson and Teeter who successfully solved the crambin protein 
structure by using the anomalous scattering of sulfur atoms present in six cysteine residues, which 
led to the structure determination of the protein composed of 46-residues (Hendrickson and Teeter, 
1981). However, it was not until the late 1990s that the anomalous effect of sulfur was again used 
for phasing novel structures. The main reason for such a long gap is the requirement of very 
accurate diffraction data (Ramagopal et al., 2003). However, in recent years, thanks to the increased 
availability of synchrotron beamlines, cryocooling techniques and advances in phasing algorithms, 
S-SAD is becoming a powerful tool in protein X-ray crystallography (Ramagopal et al., 2003). The 
K absorption edge of sulfur atom lies in the long wavelength region of X-ray radiation, at 5.02   
(Cromer, 1983). In order to obtain a strong enough anomalous signal, the wavelength of the incident 
X-ray beam needs to be close to the sulfur absorption edge. Longer wavelengths due to absorption 
and scattering tend to give poor quality data. A wavelength in the range 1.5 - 2.0   appears to be 
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optimal for S-SAD phasing (Kwiatkowski et al., 2000; Weiss et al., 2001). The anomalous 
scattering contribution of this atom at various wavelengths is accessible at the laboratory or the 
synchrotron source. The latter is far more intense allowing to collect more data (hence more 
accurate due to averaging) in less time, whereas, data collection times are very long using in-house 
machines, because of the shorter wavelength used (smaller anomalous signal) and lower intensity 
(Ramagopal et al., 2003).  
S-SAD offers a number of attractive features. With sulfur inherently present as an element in almost 
all proteins there is no need to modify the protein or crystal. When S-SAD is employed, a single 
data set collected from the native protein is enough to solve the entire structure. In fact, it has been 
reported that S-SAD would be a favourable method to obtain the initial phasing in small to medium 
proteins of 100 to 200 residues, with an approximate ratio of one sulfur atom per 6 kDa (Lartigue et 
al., 2004). The substitution of methionine (Met) with selenomethionine (SeMet), often required to 
solve new protein structures, is not needed in this case. The incorporation of SeMet has not always 
been successful and a number of SeMet protein crystals have failed to grow. The trial-and-error 
procedure of making heavy-atom derivatives is not required in S-SAD phasing. This conventional 
procedure often decreases the quality of crystal diffraction. The latter approach along with SeMet 
preparations remain however the “rate-limiting step” for solving structures by MAD technique 
(Yang, 2003).  
Another attractive feature of S-SAD is overcoming model bias which is a major problem in 
molecular-replacement (MR) structure determination. This issue in MR phasing can complicate 
model building in parts of the structure where the protein in question and the search model differ. 
When S-SAD is incorporated in MR, a strategy denoted “MRSAD” , not only the anomalous 
scatterer sub-structurecan be quickly defined from the MR solution but also the model bias, typical 
to MR, can be overcome given that the phases from SAD and MR are virtually independent 
(Schuermann and Tanner, 2003). 
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S-SAD phasing has been successfully tried on several structures (Chen et al., 1991; Brodersen et al., 
2000; Liu et al., 2000; Wu et al., 2001). However, despite all the advantages offered, S-SAD 
phasing is not yet at the level where it is a standard method for automated structure determination 
using existing beamlines and current software tools (Doutch et al., 2012). 
 
5.2 Materials and methods/results 
PA1645 was identified from genetics as an essential protein. It has no human homologues and as 
such is an interesting target for drug development. PA1645 is annotated as a hypothetical protein 
from PA01. It has no characterised homologue in the protein database (Moynie et al., 2013). The 
structure of the protein could not be predicted from its sequence, which identified the need for the 
structural characterisation of the protein using X-ray crystallography, in order to investigate its 
function.PA1645 is a 135 residue protein with the following sequence: 
 
        10         20         30         40         50         60  
MRPVLPLLLS LSLCAPALAD WSGPIEQPLW SLPAAPGLSR WLIVHNLSSA AADGLYHVEV  
        70         80         90        100        110        120  
LERRQGQQPW QFQRLAAHLA LTEQALRASI VAPLKRGGVY PESYQFAYRQ WQERQAAGQA  
       130  
PVCRRTVDEC LRAPD  
 
PA1645 was immediately truncated to residues 20 – 135 as the first 19 residues are predicted to be 
signal peptide (http://www.cbs.dtu.dk/services/SignalP/). Signal peptides are present at the N-
terminus of the majority of the newly synthesised proteins that are destined towards the secretory 
pathway (Blobel and Dobberstein, 1975). PA1645 was predicted computationally to be involved in 
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type I secretion system. DNA encoding the gene for PA1645ΔN19 was amplified from P. 
aeuroginosa strain PA01 using 5’- agggcgCCATGGgtcccgtattgccgctgttgctg-3’ and 5’- 
gaattcGGATCCtcagtccggcgcccgcaggcactc -3’ primers, that were designed to include Nco1 and 
BamH1 restriction enzymes recognition sites (shown in capitals in the primers sequence) 
respectively to facilitate cloning. The amplified gene was cloned into both pEHISTEV and 
pEGFPHISTEV expression vectors (Liu, 2009). The pEHISTEV-PA1645ΔN19 protein proved to 
be insoluble and so all further work was performed from the pEGFPHISTEV- PA1645ΔN19 
construct.  
 
5.2.1. Protein Overexpression and purification 
In order to overexpress PA1645N19, E. coli cells transformed with the plasmid were grown at 15 
°C in tryptose phosphate broth medium containing 30 µg/ml kanamycin until the OD600 reached 0.6 
- 1. Expression of the protein was then induced by the addition of 0.1 mM IPTG. After a further 45 
hours of culture cells were harvested by centrifugation (10 minutes, 6500 rpm, 4 °C).  
The cell pellet was resuspended in a lysis buffer containing 20 mM sodium phosphate pH 7.4, 500 
mM sodium chloride, 10% glycerol, 10 mM imidazole and 1 mg/ml hen egg-white lysozyme. The 
viscosity of the mixture was further reduced by the addition of 20 µg/ml DNAse. The cells were 
lysed by cell disruptor at 30 kpsi. The suspension was centrifuged at 20,000 rpm and 4 °C for 20 
minutes. The supernatant was filtered using 0.45 µm filter before it is passed through a 5 ml IMAC 
column pre-loaded with nickel sulfate. The column was then washed for 250 ml using a buffer 
containing 20 mM sodium phosphate pH 7.4, 500 mM sodium chloride, 10 % glycerol and 30 mM 
imidazole before elution from the column using a buffer containing 20 mM sodium phosphate pH 
7.4, 500 mM sodium chloride, 10 % glycerol and 300 mM imidazole. The protein fractions were 
pooled together after elution.  
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The pooled protein fractions were applied to a desalting column using the wash buffer containing 
20 mM sodium phosphate pH 7.4, 500 mM sodium chloride, 10 % glycerol and 30 mM imidazole. 
EDTA and DTT were added to the wash buffer at concentrations of 0.5 mM and 1 mM, 
respectively.  
In order to cleave the green fluorescent protein (GFP) tag of the protein, tobacco etch virus (TEV) 
protease was added to a ratio of 1 mg of TEV to 15 mg of protein and left on the roller mixer for 
one hour at room temperature. Each step of the purification was monitored by sodium dodecyl 
sulfate polyacrylamide gel electrophoresis (SDS-PAGE). After cleavage, the protein solution was 
purified using IMAC column to remove the His tag and TEV, with the flow-through collected and 
concentrated (figure 5.1). 
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Figure 5.1: SDS-PAGE gel showing the protein samples from the overexpression stage up to one 
hour post-TEV cleavage.Elutions 1, 2 and 3 are elution samples taken from various points in the 96-
well block after IMAC column purification (Elution 1 - first fraction from well A4, Elution2 - 
middle fraction from well A8 and Elution 3 - is the last fraction from well B12). The expected 
molecular weight of the protein is around 43 kDa prior to TEV cleavage. The expected molecular 
weight of the protein is around 13 kDa post-TEV cleavage.  
 
The concentrated protein was further purified by gel filtration using Superdex 75 16/60 column. 
The final buffer for crystallisation contained 10 mM Tris pH 7.5, 150 mM sodium chloride. Once 
the gel filtration run was completed, a gel was run to identify which fractions to combine and 
concentrate (figures 5.2 and 5.3a). The identity of the protein was confirmed by mass spectrometry 
(figure 5.3b) 
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Figure 5.2: Gel filtration results for PA1645. Below are the calibration curves for the molecular 
weights in Da. The protein elutes from gel filtration in three peaks (1, 2 and 3). Peak 1 represents 
protein aggregates eluting at a volume corresponding to over 670 kDa. Peak 2 is analogous in size 
to the proposed trimer around 40 kDa. Peak 3 elutes at a volume consistent with the monomer at 
around 13 kDa.  
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Figure 5.3a: SDS-PAGE gel showing pure protein fractions from peak 2 (B1, C1, C2, C3, C4, C5, 
C6 and C7) and peak 3 (C9, C10, C11, C12, D12, D11, D10, D9, D8, D7, D6 and D5) which were 
combined and concentrated separately. 
 
Figure 5.3b: Mass spectrometry results for PA1645N19.  
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The optimal protein concentration for crystallisation trials was determined by using the pre-
crystallisation test (Hampton Research). The protein was mixed with two representative 
precipitants, one containing ammonium sulfate and the other PEG4000, to determine the protein 
concentration at which light precipitation is observed for both conditions. This concentration was 
then used for crystallography. As a result of these tests, the combined fractions were concentrated to 
6 mg/ml for the peak corresponding to the monomer and 4 mg/ml for the peak corresponding to the 
trimer.  
 
5.2.2. Crystallisation 
Initial crystallisation conditions for PA1645N19 were identified using screening by sitting drop 
vapour diffusion with a variety of crystallisation screens including three stochastic screens prepared 
in-house alongside the commercial crystallisation screens JCSG and Pegs. The Cartesian Honeybee 
963 was used to set up 96-well crystallisation plates at two protein concentrations. The drops 
consisted of 0.15 µl protein + 0.15 µl precipitant and 0.3 µl protein + 0.15 µl precipitant, with 75 µl 
precipitant per reservoir for each plate. All screening experiments were incubated at 20 °C.  
Small crystals grew at various conditions but the best crystals were obtained at 1.37 M magnesium 
sulfate, 0.1 M sodium acetate pH 5, 0.09 M sodium citrate. These crystals diffracted to about 4 Å. 
Optimisation of this condition was performed using a Hamilton Microlab Star to design and build a 
screen around the original mother liquor, with 0.1 M sodium citrate or sodium actetate (pH 4.5 - 
5.5) as buffer, ammonium sulfate (1.1 M - 2.0 M), magnesium sulfate (1.0 M - 1.6 M) or lithium 
sulfate (0.5 M - 1.0 M) as precipitants and sodium citrate (unbuffered 0.06 M - 0.2 M ) or sodium 
acetate (unbuffered 0.06 M - 0.2 M) as salt. As before the crystallisation screens were set on the 
Cartesian Honeybee 963. All screening experiments were incubated at 20 °C and imaged at regular 
intervals with a Rhombix-Thermo imager.  
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The optimisation screen resulted in good quality crystals that grew in clusters to full size in one 
week from 0.1 M sodium citrate pH 4.5, 0.641 M lithium sulfate, 0.18 M sodium acetate unbuffered 
(figure 5.4).  
  
Figure 5.4: Protein crystal clusters formed by PA1645 N19 (grown from monomer sample) from: 
(a)0.1 M sodium acetate pH 4.5, 0.641 M lithium sulfate , 0.12 M sodium citrate (b) 0.1 M sodium 
citrate pH 4.5, 0.641 M lithium sulfate, 0.18 M sodium acetate (c) 0.1 M sodium acetate pH 5, 0.74 
M lithium sulfate , 0.14 M sodium acetate. 
 
5.2.3. Data collection 
The crystals used for data collection were obtained from 0.641 M lithium sulfate, 0.18 M sodium 
acetate (unbuffered), 0.1 M sodium citrate pH 4.5 (figure 5.4b).Native protein crystals were 
cryocooled to -173 °C using a cryoprotectant of mother liquor containing 12-25 % glycerol prior to 
data collection. A single wavelength anomalous dispersion (SAD) dataset was collected to 1.98   
resolution on BMIO3 at the Diamond light source Oxfordshire. The incident X-ray beam had a 
wavelength of 1.6  . 2400 frames were recorded with a crystal-to-detector distance of 119.29 mm 
as non-overlapping 0.5 º oscillations with 0.5 s exposure time per image.  
An example of the diffraction pattern obtained is shown in figure 5.5.  
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Figure 5.5: X-ray Diffraction pattern of PA1645N19 crystals obtained at the BMIO3 beamline at 
the Diamond Light Source, Oxfordshire. 
 
Data were auto-processed by Xia2 at Diamond. This software auto-indexes, integrates, scales, and 
truncates the data to generate trial dataset (Winter, 2010). The results suggested that the crystal 
lattice belonged to the I4122 space group, with unit cell dimensions of a = 126.15, b = 126.15, c = 
126  , α = β = γ = 90º. Data collection statistics are given in table 5.2. 
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Wavelength ( ) 1.6 
Resolution ( ) 89.07-1.98 (2.03-1.98) 
Space Group I4122 
Temperature (K) 100 
  a = b = 126.2 c = 126 , 
Unit-cell parameters ( ,º) α = β = γ = 90º 
Solvent content (%) 55 
Unique reflections 35545 (2600) 
Total reflections 2591494 (192485) 
Average I/σ (I) 56.5 (9.4) 
Multiplicity 72.9(74.0) 
Completeness 99.9 (99.9) 
Rmerge 0.086(0.747) 
Anomalous completeness 99.9 (99.9) 
Anomalous multiplicity 38.2 (38.2) 
Anomalous correlation 0.33 (0.051) 
Anomalous slope 1.261 (0.0) 
Table 5.2: Data collection statistics from Xia2 for PA1645N19 crystal. Values in parentheses refer 
to the highest resolution shell.  
 
Data were also processed manually. Images were indexed using MOSFLM and merged with 
SCALA. Initial indexing suggested the crystals to be cubic a = b = 125.5, c = 125.32  , α = β = γ = 
90º. However data could not be satisfactorily integrated in a cubic space group.In automated Xia2 
the CCP4 program POINTLESS suggested the space group was I4122 (body cantered tetragonal). 
Since a = b and are very close to c, there was a concern that the crystal was in fact cubic (a = b= c). 
To confirm the assignment of space group by POINTLESS the data were further examined using 
XTRIAGE (www.phenix-online.org). This confirmed manual processing results which showed that 
processing in a cubic space group gave an Rmergeover 40%. Data collection statistics are given in 
table 5.3.  
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Wavelength ( ) 1.6 
Resolution ( ) 36.22-1.95 (2.06-1.95) 
Space Group I4122 
Temperature (K) 100 
 
a = 125.52, b = 125.52, c = 
125.32 , 
Unit-cell parameters ( ,º) α = β = γ = 90º 
Solvent content, Trimer (%) 55 
Unique reflections 36673 (5280) 
Total reflections 2432422 (350093) 
Average I/σ (I) 32.3 (9.6) 
Multiplicity 72.9 (74.0) 
Completeness 100 (100) 
Rmerge 0.139 (0.553) 
Table 5.3: Data statistics for PA1645N19 crystal. Values in parentheses refer to the highest 
resolution shell.  
 
It was decided to use the Xia2 processing (table 5.2) as it had given better statistics, most notably 
the Rmerge value (a robust indication of data consistency) of 0.086 vs. 0.139. 
SHELXC/D/E suite of programs (Sheldrick, 2008) was used to analyse the heavy-atom substructure 
of the dataset. SHELXC examines the anomalous difference in the data. It calculates the size of the 
anomalous difference divided by the standard deviation of the difference. The larger the value, the 
more reliable the anomalous difference. Typically differences of less than 1 are regarded as 
unreliable. Therefore, where the ratio drops below 1 is a guide to where the effective resolution of 
the anomalous measurement is. This resolution can be helpful in SHELXD. These data were cut off 
where the graph drops below 1 which corresponds to a resolution of 2.5   (figure 5.6)2.  
                                                 
2
 S-SAD phasing was carried out with the assistance of Pr. J H Naismith. 
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Figure 5.6: Resolution cut-off for the anomalous signal as estimated from the ShelxC output.  
 
SHELXD is a direct methods program. It treats the anomalous difference in a way that mirrors a 
small molecule dataset. SHELXD starts by assigning a random set of atoms which fit the anomalous 
difference Patterson function. These positions are used to calculate phases which are used to 
identify more peaks by difference Fourier. The program repeats this procedure for a user chosen 
number of trials. Each trial is assigned a measure of agreement with the Patterson map and the 
correlation with the data. These are plotted as histograms. Typically a correct solution occurs 
infrequently but has a much higher correlation with the data. 
SHELXD was used to solve the substructure by locating the anomalous scattering atom (in this case 
sulfur). The PA1645N19 trimer possesses six sulfur atoms present in cysteines. In total SHELXD 
identified ten sulfur sites. These sites were later confirmed by the final structure to correspond to 
the sulfur atoms from four cysteine residues present in protein. Interestingly, six non-protein sulfur 
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atoms were also identified. These were attributed to sulfate in the protein crystal which was used as 
precipitant (lithium sulfate) during the crystallisation stage (figures 5.7a and 5.7b and 5.8).  
In the histogram (figure 5.7a) a clear bimodal distribution is observed. The noise solutions cluster 
around an overall correlation coefficient (CCall) of around 10. A much smaller number of solutions 
cluster around 25 and are separate from the noise. This pattern has been found to be characteristic of 
a correct solution. In figure 5.7b, the occupancy of each site is plotted. Sharp discontinuities are 
observed at six sites and at ten sites. A single sharp discontinuity is normal in a correct solution. 
The pattern was considered promising when considered alongside figure 5.7a. The final sulfur atom 
sites are labelled on the diagram showing the peaks were in fact correct. 
 
Figure 5.7a: SHELXD histogram plotting number of solutions against the overall correlation 
coefficient (CCall).  
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Figure 5.7b: The site occupancy of SHELXD located sites. Labelled are the final sulfur atoms from 
the structure.  
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Figure 5.8: Images taken from COOT (Emsley et al, 2010) showing superimposition of fa_pdb 
from SHELXD occupancy plot and the pdb from PA1645 in order to identify the sulfuratoms with 
high site occupancy. (a) SO4 /peak 1, (b) Cysteine 123 chain B/peak 2, (c) SO4 /peak 4, (d) SO4 
/peak 5, (e)Cysteine 123 chain C/peak 6, (f) SO4 /peak 7, (g) SO4 /peak 8, (h) Cysteine 123 chain 
A/peak 3 and Cysteine 130 chain A/peak 9 involved in SS bridge, (i) SO4 /peak 10.  
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Direct methods with a single dataset produce valid solutions for x y z and -x -y -z. Although 
mathematically indistinguishable, only one hand will give a map that is physically reasonable for a 
protein. SHELXE refines phases by modifying the map in real space. In the resulting modified phase 
map the contrast between a volume defined as solvent and that defined as protein is measured. A 
perfect solution would as the modification recycles converge to have a high contrast (protein vs. 
solvent). The wrong hand does not improve since the density has no physical meaning. 
SHELXE calculated modified electron density map (solvent flattening) for both hands of the 
SHELXD solution. A correct solution will show strong divergence between the correct and incorrect 
hand. As can be seen in figure 5.9a there is indeed a clear difference in contrast between both hands 
with the original hand showing a better contrast which indicates a good SHELXE solution. This is 
best illustrated with the maps from SHELXE from original (figure 5.9b) and the one from the 
inverted (figure 5.9c). Visual inspection of these two electron density maps confirms one hand gives 
protein structure whereas the wrong hand is not meaningful.  
 
 
 
 179 
 
 
Figure 5.9: (a) Density modification using SHELXE. The contrast is plotted in both hands. The 
resulting electron density maps are shown for both hands. Map (b) from original, Fobs Φ captured 
at 1σ.  
 
A polyalanine model of the structure was built using an as yet un-released version of SHELXE 
obtained with thanks from the program author George Sheldrick (Sheldrick, 2010). Chain tracing 
was completed using Buccaneer (Cowtan, 2006) as part of the ccp4 suite (figure 5.10) (Bailey, 
1994).The model was then refined in COOT (Emsley et al., 2010) and final refinement was 
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completed using REFMACv5.6 (Murshudov et al., 1997) as part of ccp4 suite (table 5.4). The 
structure was refined to a Rfactor = 0.17 and Rfree = 0.19.  
 
Figure 5.10: Electron density map from Buccaneer showing the completion of chain tracing, Fobs 
(FWT, PHWT) contoured at 1.5 σ.  
  Initial Final 
R factor 0.192 0.1762 
R free 0.2094 0.1923 
Rms Bond Length ( ) 0.0108 0.0088 
Rms Bond Angle (deg) 1.2842 1.2059 
Rms Chir Volume 0.0825 0.078 
B-factors (Å
2
) atoms A (948)  42 
B-factors (Å
2
) atoms B (947)  41 
B-factors (Å
2
) atoms C (956)  46 
B-factors (Å
2
)SO4 (11)  60 
Waters (Å
2
) (246)  46 
Ramachandran outliers  0.88 % 
Poor rotamers  0.00 % 
Molprobity Score/centile  1.11/100 
Table 5.4: Refinement Statistics table. 
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The structure was validated using Molprobity (Chen et al., 2010). Ramachandran outliers value 
came up as 0.88 % which is higher than the goal value of 0.2%. Outliers were checked and were 
found to be Gly 118 in every subunit. Gly 118 sits on the top of helix α2 (figure 5.11). Examination 
of the electron density map shows that Gly 118 to be well ordered in all three subunits. The reason 
for that unusual conformation may be the tight turn between residues Gln 115 to Gly 118. The 
coordinates with the PDB file of the structure have been deposited in the protein data bank under 
entry code 2xu8. All residues are ordered in each monomer. The structure has 3 molecules in the 
asymmetric unit. The average RMSD of monomers in trimer is 0.22 Å for 116 common calpha 
atoms. Appendix D shows the pdb validation report for PA1645 structure.  
 
Figure 5.11: View of the tight turn between residues Gln 115 to Gly 118. The latter sits on the top 
of helix α2. 
 
 182 
 
5.3. Discussion 
5.3.1. Structural analysis  
The crystal structure of the monomer consists of five stranded antiparallel β sheets and four short α-
helices (figure 5.12). There is an extended/elongated loop between α3 and α4. The very short α4 
helix is at the contact point between each two monomers and may probably be serving as a hook. 
One large loop protrudes from between strands 3 and 4(figure 5.12).  
 
Figure 5.12: View of PA1645 monomer and trimer structure with disulfide bonds highlighted. 
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When considered in the trimer these loops form an apex to the structure. On the opposite side of the 
trimer, helix 3 from each monomer packs in a manner akin to an angled propeller creating funnel 
like shape that points to a basically charged surface at the base of the structure. However, the funnel 
is partially blocked by residue(s) Q105 creating a shallow triangular basin lined by acidic residues 
D53 and E113 at the entry point and Q105 at the basin. PA1645 also binds eleven SO4 molecules 
most likely as a consequence of the crystallisation conditions. Interestingly, one of the SO4 ions sits 
just below the trio of Q105 residues and is anchored by a network of interactions with water 
molecules. There are no direct contacts with the protein. Q105 partially blocks the funnel which 
suggests that this SO4 most likely entered from the opposite end of the protein at the apex created by 
the loop between strands 3 and 4. Each of the three pores created by the protruding Q105 are 
blocked in this structure by SO4.Athough in the protein’s natural environment it is likely that these 
sites are either open allowing access through the funnel or bind alternative molecules (figure 5.12).  
Analysis of the contacts between monomers using the PDBe PISA server showed that the interface 
is weak. The average buried surface area between each monomer (interface) is 968Å
2
. The CSS 
(complexation significance score) which indicates how significant the interface is for assembly 
formation, was found to be as low as 0.194 for all interfaces, suggesting that the proposed trimeric 
arrangement may be unstable and possibly not biologically relevant. This apparent instability 
mirrors the gel filtration results which showed a mixture of trimer and monomer (figure 5.2). There 
are potentially 12 H-bonds across interfacing monomers. This compares with a buried surface area 
of 536Å
2
 and seven H-bonds for the Plasmodium falciparum dUTPase, a confirmed protein trimer 
of similar size to PA1645. Interestingly, the CSS for the dUTPase is only 0.397. This data suggests 
although the CSS for PA1645 is less than 1, it does not preclude the protein being a trimer. 
The electrostatic potential surface PA1645N19 indicates that the protein does not possess an 
extensive charged cleft. This suggests that there is no potential nucleic acid binding site (positive 
potential) (figure 5.13).  
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Figure 5.13:The electrostatic surface maps show that there are no large patches of positive charge 
(blue) that would indicate nucleic acid binding. 
 
Comparison of the PA1645 structure against those in the Protein Data Bank (PDB) using both 
softwares Dali and SSM (PDBe) has revealed no homologous structure to the protein, suggesting 
that this is a novel fold. 
 
5.4. Conclusion and future work 
PA1645ΔN19 from P. aeruginosa strain PA01 was purified and crystallized. The crystals used for 
data collection were obtained from 0.64 M lithium sulfate, 0.18 M sodium acetate (unbuffered) and 
0.1 M sodium citrate pH 4.5. Crystals were cryoprotected by doping the mother liquor with glycerol 
prior to data collection. Data were collected at Diamond on beamline IO3. Phases were determined 
using Anomalous scattering from sulfur atoms collected to 1.98   resolution at wavelength 1.6  . 
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The structure was refined by methods outlined in the main text. Final coordinates have been 
deposited in the protein data bank under entry code 2XU8. All residues are ordered in each 
monomer. The structure has three molecules in the asymmetric unit.  
 However there are questions regarding the relevance of the proposed trimeric arrangement. An 
analysis of the oligomerisation state of the protein with PISA returns a low CSS of 0.194, whereas 
the protein elutes from gel filtration in two peaks one of which is analogous in size to the proposed 
trimer around 40 kDa the other peak is a monomer around 13 kDa. Dynamic light scattering (DLS) 
experiment also known as photon correlation spectroscopy or quasi-elastic light scattering will be a 
useful experiment to conduct in order to provide evidence for the protein’s multiple oligomeric 
states in solution. 
PA1645 is a novel fold and no homologous structure to the protein has yet been found. This has 
made it very difficult to determine function. It is therefore worth considering conducting a primary 
fragment-based screening for PA1645 binding by following the same protocol described in figure 
4.11, which may help obtain further information about its function and potential inhibition.  
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CHAPTER SIX 
 
Conclusions and future work  
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6.1. Conclusions and future work to the application of FBDD approach to RmlA  
This thesis described attempts to identify potential inhibitors to P. aerguinosa RmlA protein. A 500 
“Rule of 3” Fragment Library (Maybridge) was investigated using a number of fragment-based 
screening techniques. The first approach was the application of DSF screening to detect ligands that 
bind and stabilise RmlA protein. 21 compounds were found to increase the protein’s stability. The 
library was then screened by two ligand-based NMR experiments, STD and WaterLOGSY. 106 
compounds gave positive results in both experiments. These hits were then tested by a simple STD 
competition binding with dTTP, a natural RmlA substrate, in order to identify those compounds 
binding at the active or allosteric site. 21 out of the 106 compounds were observed to compete with 
dTTP.A coupled enzyme assay was used to monitor RmlA activity in the presence of those 
compounds that tested positive in the DSF screening and those compounds that were observed to 
compete with dTTP. Only one compound, 3-pyridin-3-ylaniline, showed significant inhibition of 
the enzyme activity.  
Ligands that bind to RmlA protein can vary in terms of binding specificity and affinity. They also 
have different effects on the protein’s stability. This is where DSF screening and ligand-based NMR 
screening are complementary, with their key strengths in detecting interactions. In future primary 
screens, especially where larger libraries are used, attempts can be made to narrow down the library 
size into specific binders and stabilisers. This can be achieved by using DSF screening as first filter. 
The main reason for this is that it allows the elimination of those compounds that destabilise the 
protein in a significant way or cause its complete denaturation, which is usually associated with 
non-specific binding and would therefore test as false positive in ligand-based NMR experiments. 
In addition to this, excluding such compounds is important when applying more advanced 
techniques, such as co-crystallisation experiments where the stability of the protein must be verified 
in the soaking solution.On the other hand, those compounds that stabilise the protein, generally due 
to specific binding, can be identified and investigated further. Unlike ligand-based NMR, DSF sets 
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no affinity limit, which allows the identification of tight binders. Further, a large number of 
compounds up to 384 can be screened at the time and results obtained within a few hours. 
Ligand-based NMR could then be used in the next screening stage to confirm the binding of those 
compounds that tested positive in DSF. It can also be used to test the compounds that show no or 
little negative effect on protein stability, because of its unique sensitivity in detecting very weak 
interactions.49 out of the 106 compounds which tested positive in both STD and WaterLOGSY 
experiments were found to significantly destabilise the protein or cause its complete denaturation in 
the DSF screening. Such an effect is usually associated with non-specific interactions. This group of 
49 compounds demonstrate the limitation of ligand-based NMR techniques in yielding false 
positives arising from non-specific binding.  
Another point worth noting is that STD and WaterLOGSY seem to agree in almost all cases. 
Therefore, it is worth considering running only WaterLOGSY for future screens for RmlA binders. 
Not only this technique is more sensitive but also generates straightforward results with no further 
processing required. Processing NMR data manually and changing NMR samples between each 
experiment is rather time consuming and puts a limit on the size of the library screened as well as 
the number of target proteins tested. Now, with the availability of an automated system to run NMR 
samples over a number of days as well as a processing software named Amix, written by Brucker,a 
larger library size could be screened, which increases the chances of hit finding.  
The identified compounds from the primary screening stage need to be further confirmed and 
validated using more advanced techniques. For potential hit validation i.e. identifying the binding 
site and mode of binding, target-based NMR techniques such as chemical shift mapping using 
15
N 
or 
13
C labelled protein could be used. Targets to which this approach is applicable have however 
restricted size to a maximum molecular weight of 100 kDa (Klages et al., 2007). With RmlA being 
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a homotetramer with a monomer size around 34 kDa, chemical shift mapping experiments may not 
be possible. Crystallography studies remain the best tool to investigate these compounds further.  
 
6.2. Conclusions and future work to PA1645 structure 
PA1645ΔN19 from PA01 was purified and crystallised. The crystals used for data collection were 
obtained from 0.64 M lithium sulfate, 0.18 M sodium acetate (unbuffered) and 0.1 M sodium citrate 
pH 4.5. Phases were determined using anomalous scattering from sulfur atoms collected to 1.98   
resolution. The incident X-ray beam had a wavelength of 1.6  . The structure has been refined and 
final coordinates have been deposited in the protein data bank under entry code 2XU8. All residues 
are ordered in each monomer. The structure has three molecules in the asymmetric unit. However 
the results from solution and crystal disagree on the proposed trimeric arrangements. 
 DLS will be a useful experiment to conduct in order to investigate further the protein’s multiple 
oligomeric states in solution. No homologous structure to the protein has yet been found, suggesting 
that PA1645 is a novel fold. In order to investigate the structure of protein, spectroscopic methods 
such as NMR and EPR are worth considering. These methods can offer valuable information on the 
structure and behaviour of, through its investigation under conditions that are more appropriate for 
simulation of biological systems, rather than single crystals which may not be biologically active. It 
is also worth considering conducting a primary fragment-based screening for PA1645 binding. The 
same protocol described in figure 4.11chapter three can be followed to screen for PA1645 binders, 
which will help in providing information about its function and potential inhibition.  
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6.3. Publications 
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PLATE 
No 
WELL 
POSITION 
MOLWEIGHT Name 
1 A1 129.11 3,5-difluoroaniline 
1 B1 110.16 2-ethyl-4-methyl-1H-imidazole 
1 C1 131.18 7-methyl-1H-indole 
1 D1 168.20 9H-beta-carboline 
1 E1 173.60 pyridin-3-ylacetic acid hydrochloride 
1 F1 190.29 1-(2,3-dimethylphenyl)piperazine 
1 G1 125.15 3-fluorobenzylamine 
1 H1 180.22 1-(4-fluorophenyl)piperazine 
1 A2 129.16 3-piperidinecarboxylic acid 
1 B2 144.18 3-phenyl-1H-pyrazole 
1 C2 169.57 6-chloro-1,3-benzoxazol-2-ol 
1 D2 165.22 3-methyl-1,3-benzoxazole-2(3H)-thione 
1 E2 133.15 1H-indazol-5-amine 
1 F2 175.19 methyl 1H-indole-3-carboxylate 
1 G2 140.14 3-(2-furyl)propanoic acid 
1 H2 126.11 2-methyl-3-furoic acid 
1 A3 106.13 2-vinylpyrazine 
1 B3 112.13 (5-methyl-2-furyl)methanol 
1 C3 190.27 4-(2-methyl-1,3-thiazol-4-yl)phenylamine 
1 D3 184.20 2-amino-5-phenyl-3-furonitrile 
1 E3 147.22 8-methyl-1,2,3,4-tetrahydroquinoline 
1 F3 194.23 ethyl 3-(4-hydroxyphenyl)propanoate 
1 G3 178.23 4-morpholinoaniline 
1 H3 176.26 2-piperidinoaniline 
1 A4 178.23 2-morpholinoaniline 
1 B4 180.20 3-(2-methoxyphenyl)propanoic acid 
1 C4 183.21 5-amino-2-(1H-pyrrol-1-yl)benzonitrile 
1 D4 173.57 3-chloro-4-fluorobenzamide 
1 E4 172.13 1-(3,5-difluoro-2-hydroxyphenyl)ethan-1-one 
1 F4 177.25 N1-(4-propylphenyl)acetamide 
1 G4 184.65 6-chloro-1,3-benzothiazol-2-amine 
1 H4 176.26 4-piperidinoaniline 
1 A5 112.13 6-methyl-2,3,4,5-tetrahydropyridazin-3-one 
1 B5 180.20 2-(2,5-dimethylphenyl)-2-hydroxyacetic acid 
1 C5 166.10 
1-methyl-3-(trifluoromethyl)-4,5-dihydro-1H-
pyrazol-5-one 
1 D5 166.18 3-(2-hydroxyphenyl)propanoic acid 
1 E5 109.13 1-(1H-pyrrol-3-yl)ethan-1-one 
1 F5 176.14 4-(trifluoromethyl)benzene-1,2-diamine 
1 G5 136.13 2-amino-6-fluorobenzonitrile 
1 H5 152.58 2-amino-6-chlorobenzonitrile 
1 A6 192.24 4-(2-amino-1,3-thiazol-4-yl)phenol 
1 B6 122.17 3-methylbenzene-1,2-diamine 
1 C6 127.17 thiophene-2-carboxamide 
1 D6 166.10 1-methyl-5-(trifluoromethyl)-1H-pyrazol-3-ol 
1 E6 169.65 1,2,3,4-tetrahydroisoquinoline hydrochloride 
1 F6 180.20 methyl 2-(3-methoxyphenyl)acetate 
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1 G6 148.20 7-methylindan-4-ol 
1 H6 187.20 methyl isoquinoline-3-carboxylate 
1 A7 190.24 7-methyl-2,3-dihydro-1H-inden-4-yl acetate 
1 B7 109.13 pyridine-2,3-diamine 
1 C7 176.65 quinuclidin-3-one oxime hydrochloride 
1 D7 174.24 1-butoxy-4-eth-1-ynylbenzene 
1 E7 132.16 1-eth-1-ynyl-4-methoxybenzene 
1 F7 167.25 1,7,7-trimethylbicyclo[2.2.1]heptan-2-one oxime 
1 G7 152.15 1-(2,6-dihydroxyphenyl)ethan-1-one 
1 H7 144.18 isoquinolin-3-amine 
1 A8 176.17 3-oxoindane-1-carboxylic acid 
1 B8 150.18 1-(2-hydroxy-5-methylphenyl)ethan-1-one 
1 C8 168.16 4-(trifluoromethyl)cyclohexan-1-ol 
1 D8 166.14 4-(trifluoromethyl)cyclohexan-1-one 
1 E8 184.21 4-oxo-4-(2-thienyl)butanoic acid 
1 F8 144.18 quinolin-2-amine 
1 G8 190.67 
8-methyl-8-azabicyclo[3.2.1]octan-3-one oxime 
hydrochloride 
1 H8 121.18 2-ethyl-6-methylpyridine 
1 A9 178.28 N,N-diethyl-N-[2-(2-pyridyl)ethyl]amine 
1 B9 178.19 1-(2,3-dihydro-1,4-benzodioxin-6-yl)ethan-1-one 
1 C9 175.19 methyl 1H-indole-7-carboxylate 
1 D9 175.19 4-hydroxy-1-methyl-1,2-dihydroquinolin-2-one 
1 E9 152.19 bicyclo[3.3.1]nonane-2,6-dione 
1 F9 165.19 3,4-dihydro-2H-1,5-benzodioxepin-7-amine 
1 G9 177.23 3-phenyl-1,2,4-thiadiazol-5-amine 
1 H9 189.21 3-(1H-indol-3-yl)propanoic acid 
1 A10 191.27 4-(2-methoxyphenyl)piperidine 
1 B10 166.22 3a,6a-dimethylperhydropentalene-2,5-dione 
1 C10 186.21 4-phenoxyphenol 
1 D10 154.21 4-hydroxy-1-methylbicyclo[2.2.2]octan-2-one 
1 E10 170.21 2-hydroxybicyclo[3.2.1]octane-6-carboxylic acid 
1 F10 180.20 3,4-dihydro-2H-1,5-benzodioxepin-6-ylmethanol 
1 G10 189.21 (5-methyl-3-phenyl-4-isoxazolyl)methanol 
1 H10 122.13 3,5-dimethyl-4-isoxazolecarbonitrile 
1 A11 194.11 5-methyl-2-(trifluoromethyl)-3-furoic acid 
1 B11 185.65 
2,3-dihydrobenzo[b]furan-5-ylmethylamine 
hydrochloride 
1 C11 150.18 2,3-Dihydrobenzo[b]furan-7-methanol 
1 D11 140.14 2,5-dimethyl-3-furoic acid 
1 E11 166.18 2,3-dihydro-1,4-benzodioxin-6-ylmethanol 
1 F11 165.19 2,3-dihydro-1,4-benzodioxin-6-ylmethylamine 
1 G11 166.18 2,3-dihydro-1,4-benzodioxin-5-ylmethanol 
1 H11 166.18 2,3-dihydro-1,4-benzodioxin-2-ylmethanol 
2 A1 165.19 2,3-dihydro-1,4-benzodioxin-2-ylmethylamine 
2 B1 152.15 1,3-benzodioxol-5-ylmethanol 
2 C1 165.19 N-(1,3-benzodioxol-5-ylmethyl)-N-methylamine 
2 D1 152.15 1,3-benzodioxol-4-ylmethanol 
2 E1 184.17 (6-fluoro-4H-1,3-benzodioxin-8-yl)methanol 
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2 F1 112.08 2-furoic acid 
2 G1 112.08 3-furoic acid 
2 H1 97.12 3-furylmethylamine 
2 A2 191.25 [5-(2-pyridinyl)-2-thienyl]methanol 
2 B2 125.13 1-methyl-1H-pyrrole-2-carboxylic acid 
2 C2 110.12 2-pyrazinylmethanol 
2 D2 123.11 2-pyridinecarboxylic acid 
2 E2 123.11 nicotinic acid 
2 F2 123.11 isonicotinic acid 
2 G2 109.13 4-pyridinylmethanol 
2 H2 173.17 2-quinolinecarboxylic acid 
2 A3 173.17 quinoline-6-carboxylic acid 
2 B3 172.23 N-methyl-N-(quinolin-6-ylmethyl)amine 
2 C3 173.17 quinoline-4-carboxylic acid 
2 D3 191.19 isoquinoline-3-carboxylic acid hydrate 
2 E3 179.20 thieno[2,3-b]pyridine-2-carboxylic acid 
2 F3 165.22 thieno[2,3-b]pyridin-2-ylmethanol 
2 G3 143.17 2-methyl-1,3-thiazole-4-carboxylic acid 
2 H3 143.21 (2,4-dimethyl-1,3-thiazol-5-yl)methanol 
2 A4 179.20 1,3-benzothiazole-6-carboxylic acid 
2 B4 150.20 1,3-benzothiazol-6-amine 
2 C4 165.22 1,3-benzothiazol-2-ylmethanol 
2 D4 175.23 
N-methyl-N-[(1-methyl-1H-indazol-3-
yl)methyl]amine 
2 E4 148.16 1-benzofuran-2-ylmethanol 
2 F4 148.16 1-benzofuran-5-ylmethanol 
2 G4 147.18 1-benzofuran-5-ylmethylamine 
2 H4 133.15 1-benzofuran-5-amine 
2 A5 148.16 1H-benzimidazol-2-ylmethanol 
2 B5 115.16 1,3-thiazol-2-ylmethanol 
2 C5 175.19 (5-phenyl-1,3-oxazol-4-yl)methanol 
2 D5 112.13 (5-methyl-3-isoxazolyl)methylamine 
2 E5 190.26 (4-thien-2-ylphenyl)methanol 
2 F5 164.23 1-benzothiophen-2-ylmethanol 
2 G5 178.21 1-benzothiophene-3-carboxylic acid 
2 H5 125.17 (1,3-dimethyl-1H-pyrazol-5-yl)methylamine 
2 A6 126.16 (1,5-dimethyl-1H-pyrazol-3-yl)methanol 
2 B6 147.18 1H-indol-3-ylmethanol 
2 C6 128.15 thiophene-2-carboxylic acid 
2 D6 180.20 3,4-dihydro-2H-1,5-benzodioxepin-7-ylmethanol 
2 E6 192.24 (2-pyridin-3-yl-1,3-thiazol-4-yl)methanol 
2 F6 139.20 (1,3,5-trimethyl-1H-pyrazol-4-yl)methylamine 
2 G6 188.22 (2-methyl-5-phenyl-3-furyl)methanol 
2 H6 188.23 (5-methyl-1-phenyl-1H-pyrazol-4-yl)methanol 
2 A7 116.12 tetrahydro-2-furancarboxylic acid 
2 B7 193.24 (4-morpholin-4-yl-phenyl)-methanol 
2 C7 191.25 (2-phenyl-1,3-thiazol-4-yl)methanol 
2 D7 174.20 [4-(1H-pyrazol-1-yl)phenyl]methanol 
2 E7 173.22 4-(1H-pyrazol-1-yl)benzylamine 
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2 F7 174.20 [4-(1H-imidazol-1-yl)phenyl]methanol 
2 G7 186.21 1-[4-(1H-imidazol-1-yl)phenyl]-1-ethanone 
2 H7 190.27 3-(2-methyl-1,3-thiazol-4-yl)aniline 
2 A8 186.21 6-phenoxy-3-pyridinamine 
2 B8 189.21 (3-methyl-5-phenyl-4-isoxazolyl)methanol 
2 C8 112.13 (1-methyl-1H-imidazol-2-yl)methanol 
2 D8 185.23 (6-phenyl-3-pyridinyl)methanol 
2 E8 180.21 6-phenylnicotinonitrile 
2 F8 187.20 3-(1H-pyrrol-1-yl)benzoic acid 
2 G8 172.23 3-(1H-pyrrol-1-yl)benzylamine 
2 H8 193.23 3-(1H-pyrrol-1-yl)thiophene-2-carboxylic acid 
2 A9 179.24 [3-(1H-pyrrol-1-yl)-2-thienyl]methanol 
2 B9 182.25 
(1,3-dimethyl-1H-thieno[2,3-c]pyrazol-5-
yl)methanol 
2 C9 181.21 [5-(2-thienyl)-3-isoxazolyl]methanol 
2 D9 107.12 1-methyl-1H-imidazole-5-carbonitrile 
2 E9 188.23 (1-benzyl-1H-imidazol-2-yl)methanol 
2 F9 150.18 2,3-dihydro-1-benzofuran-2-ylmethanol 
2 G9 191.25 2H-chromene-3-carbothioamide 
2 H9 193.24 (2-morpholinophenyl)methanol 
2 A10 192.26 2-morpholinobenzylamine 
2 B10 169.19 2-(1H-pyrazol-1-yl)benzonitrile 
2 C10 187.20 4-(1H-pyrrol-1-yl)benzoic acid 
2 D10 173.21 [4-(1H-pyrrol-1-yl)phenyl]methanol 
2 E10 172.23 4-(1H-pyrrol-1-yl)benzylamine 
2 F10 178.19 3-chromanecarboxylic acid 
2 G10 127.14 (2,5-dimethyl-1,3-oxazol-4-yl)methanol 
2 H10 192.21 
2,2-dimethyl-2,3-dihydro-1-benzofuran-7-
carboxylic acid 
2 A11 178.23 
(2,2-dimethyl-2,3-dihydro-1-benzofuran-7-
yl)methanol 
2 B11 188.23 (1-methyl-5-phenyl-1H-pyrazol-4-yl)methanol 
2 C11 187.20 2-methyl-6-quinolinecarboxylic acid 
2 D11 173.21 (2-methyl-6-quinolinyl)methanol 
2 E11 147.18 1H-indol-4-ylmethanol 
2 F11 192.26 4-(morpholinomethyl)aniline 
2 G11 165.19 3,4-dihydro-2H-1,4-benzoxazin-2-ylmethanol 
2 H11 130.14 tetrahydro-2H-pyran-4-carboxylic acid 
3 A1 116.16 tetrahydro-2H-pyran-4-ylmethanol 
3 B1 177.25 [4-(1-pyrrolidinyl)phenyl]methanol 
3 C1 176.26 [4-(1-pyrrolidinyl)phenyl]methanamine 
3 D1 141.19 4-methylthiophene-2-carboxamide 
3 E1 148.16 imidazo[1,2-a]pyridin-2-ylmethanol 
3 F1 185.23 3-(2-methylpyrimidin-4-yl)aniline 
3 G1 154.19 imidazo[2,1-b]thiazol-6-ylmethanol 
3 H1 169.19 3-(1H-imidazol-1-yl)benzonitrile 
3 A2 148.16 imidazo[1,2-a]pyridin-6-ylmethanol 
3 B2 193.24 (3-morpholinophenyl)methanol 
3 C2 178.23 3-morpholin-4-ylaniline 
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3 D2 187.20 2-(1H-pyrrol-1-yl)benzoic acid 
3 E2 173.21 [2-(1H-pyrrol-1-yl)phenyl]methanol 
3 F2 172.23 [2-(1H-pyrrol-1-yl)phenyl]methylamine 
3 G2 174.20 [4-(2-furyl)phenyl]methanol 
3 H2 173.21 [4-(2-furyl)phenyl]methylamine 
3 A3 185.22 (4-pyrid-4-ylphenyl)methanol 
3 B3 190.26 (2-thien-2-ylphenyl)methanol 
3 C3 185.22 (3-pyrid-4-ylphenyl)methanol 
3 D3 191.28 2-(4-methylpiperazin-1-yl)aniline 
3 E3 187.24 3-piperidin-1-ylpyridine-2-carbonitrile 
3 F3 172.23 3-pyrrolidin-1-ylbenzonitrile 
3 G3 167.19 4H-thieno[3,2-b]pyrrole-5-carboxylic acid 
3 H3 181.21 methyl 6H-thieno[2,3-b]pyrrole-5-carboxylate 
3 A4 170.21 3-pyridin-3-ylaniline 
3 B4 185.22 (4-pyrid-3-ylphenyl)methanol 
3 C4 170.21 4-pyridin-3-ylaniline 
3 D4 176.17 benzo[b]furan-3-ylacetic acid 
3 E4 181.21 
4-methyl-4H-thieno[3,2-b]pyrrole-5-carboxylic 
acid 
3 F4 167.23 (4-methyl-4H-thieno[3,2-b]pyrrol-5-yl)methanol 
3 G4 130.14 tetrahydropyran-2-carboxylic acid 
3 H4 151.64 tetrahydropyran-2-ylmethylamine 
3 A5 175.19 1-methyl-1H-indole-5-carboxylic acid 
3 B5 146.19 1-methyl-1H-indol-5-amine 
3 C5 185.22 (4-pyrid-2-ylphenyl)methanol 
3 D5 186.21 (3-pyrimidin-5-ylphenyl)methanol 
3 E5 171.20 3-pyrimidin-5-ylaniline 
3 F5 170.21 2-pyridin-3-ylaniline 
3 G5 190.20 (5-phenoxy-2-furyl)methanol 
3 H5 188.23 [3-(1H-imidazol-1-ylmethyl)phenyl]methanol 
3 A6 173.22 3-(1H-imidazol-1-ylmethyl)aniline 
3 B6 188.23 [4-(1H-imidazol-1-ylmethyl)phenyl]methanol 
3 C6 173.22 4-(1H-imidazol-1-ylmethyl)aniline 
3 D6 180.23 (5-thien-2-yl-1H-pyrazol-3-yl)methanol 
3 E6 175.19 1-methyl-1H-indole-6-carboxylic acid 
3 F6 186.21 (4-pyrimidin-5-ylphenyl)methanol 
3 G6 177.25 2-piperazin-1-ylaniline 
3 H6 175.19 1-methyl-1H-indole-4-carboxylic acid 
3 A7 148.16 1H-benzimidazol-5-ylmethanol 
3 B7 169.18 3-(2-furyl)benzonitrile 
3 C7 188.18 2-(2-furyl)benzoic acid 
3 D7 188.23 (1-methyl-5-phenyl-1H-pyrazol-3-yl)methanol 
3 E7 188.23 (1-methyl-3-phenyl-1H-pyrazol-5-yl)methanol 
3 F7 180.23 [5-(2-furyl)thien-2-yl]methanol 
3 G7 172.20 2,3-dihydrothieno[3,4-b][1,4]dioxin-5-ylmethanol 
3 H7 167.19 
2,3-dihydrothieno[3,4-b][1,4]dioxine-5-
carbonitrile 
3 A8 185.25 
N-(2,3-dihydrothieno[3,4-b][1,4]dioxin-5-
ylmethyl)-N-methylamine 
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3 B8 175.25 3-thien-3-ylaniline 
3 C8 192.26 2-(morpholin-4-ylmethyl)aniline 
3 D8 190.26 (4-thien-3-ylphenyl)methanol 
3 E8 188.22 (5-methyl-2-phenyl-3-furyl)methanol 
3 F8 166.10 [5-(trifluoromethyl)-2-furyl]methanol 
3 G8 186.21 3-(pyridin-2-yloxy)aniline 
3 H8 192.26 (2-piperidinopyrid-4-yl)methanol 
3 A9 178.23 (2-pyrrolidin-1-ylpyrid-4-yl)methanol 
3 B9 166.18 2-(1,3-benzodioxol-5-yl)ethanol 
3 C9 190.24 4-[2-(dimethylamino)ethoxy]benzonitrile 
3 D9 142.22 2-(2-methyl-1,3-thiazol-4-yl)ethylamine 
3 E9 164.23 2-methyl-1,3-benzothiazol-6-ylamine 
3 F9 170.17 6-(2-furyl)nicotinonitrile 
3 G9 191.27 [4-(pyrrolidin-1-ylmethyl)phenyl]methanol 
3 H9 190.29 [3-(1-pyrrolidinylmethyl)phenyl]methanamine 
3 A10 176.26 3-(pyrrolidin-1-ylmethyl)aniline 
3 B10 188.23 [4-(1H-pyrazol-1-ylmethyl)phenyl]methanol 
3 C10 117.21 tetrahydrothiopyran-4-ylamine 
3 D10 118.20 tetrahydro-2H-thiopyran-4-ol 
3 E10 120.15 3-(1H-pyrrol-1-yl)propanenitrile 
3 F10 168.20 2-(1H-pyrrol-1-yl)benzonitrile 
3 G10 144.18 3-(1H-pyrrol-1-yl)pyridine 
3 H10 182.24 2-(benzylthio)acetic acid 
3 A11 173.67 5-chloro-2-(methylthio)aniline 
3 B11 110.16 1,3,5-trimethyl-1H-pyrazole 
3 C11 189.26 2,6-di(dimethylamino)benzonitrile 
3 D11 109.13 3-methyl-1,2-dihydropyridin-2-one 
3 E11 155.22 1-(2,4-dimethyl-1,3-thiazol-5-yl)ethan-1-one 
3 F11 185.25 ethyl 2-(2-methyl-1,3-thiazol-4-yl)acetate 
3 G11 128.17 azepan-2-one oxime 
3 H11 125.17 1,3,5-trimethyl-1H-pyrazol-4-amine 
4 A1 184.26 1,3-dimethoxy-2-(methylthio)benzene 
4 B1 173.23 4-(Prop-2-ynyl)thiomorpholine 1,1-dioxide 
4 C1 186.14 2-(trifluoromethyl)-1H-benzo[d]imidazole 
4 D1 177.25 N1-(4-isopropylphenyl)acetamide 
4 E1 153.57 5-chloro-2-hydroxybenzonitrile 
4 F1 141.19 1-(3-amino-2-thienyl)ethan-1-one 
4 G1 174.23 2-(1,3-benzothiazol-2-yl)acetonitrile 
4 H1 97.12 1-methyl-1H-pyrazol-3-amine 
4 A2 124.17 2-aminothiophene-3-carbonitrile 
4 B2 190.65 methyl 3-chloro-4-methylthiophene-2-carboxylate 
4 C2 184.65 4-chloro-5-methylthieno[2,3-d]pyrimidine 
4 D2 142.18 4-methylthiophene-2-carboxylic acid 
4 E2 97.12 1-methyl-1H-pyrazol-5-ylamine 
4 F2 136.08 3-(trifluoromethyl)-1H-pyrazole 
4 G2 150.10 1-methyl-3-(trifluoromethyl)-1H-pyrazole 
4 H2 193.27 
2-amino-6-methyl-4,5,6,7-tetrahydrothieno[2,3-
c]pyridine-3-carbonitrile 
4 A3 134.18 5,6,7,8-tetrahydroquinoxaline 
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4 B3 146.19 2-methylindan-1-one 
4 C3 152.15 2-hydroxy-2-phenylacetic acid 
4 D3 111.15 1,3-dimethyl-1H-pyrazol-5-amine 
4 E3 97.12 3-methyl-1H-pyrazol-5-amine 
4 F3 165.22 5-thien-2-yl-1H-pyrazol-3-amine 
4 G3 98.10 3-methylisoxazol-5-amine 
4 H3 192.62 5-chloro-4-methoxythiophene-3-carboxylic acid 
4 A4 153.23 3-(tert-butyl)-1-methyl-1H-pyrazol-5-amine 
4 B4 179.25 1-methyl-3-(2-thienyl)-1H-pyrazol-5-amine 
4 C4 173.22 1-methyl-3-phenyl-1H-pyrazol-5-amine 
4 D4 193.64 3-(4-chlorophenyl)-1H-pyrazol-5-amine 
4 E4 183.30 2-(phenylthio)ethanethioamide 
4 F4 192.31 3-(phenylthio)thiophene 
4 G4 192.31 2-(phenylthio)thiophene 
4 H4 184.28 5-(2-thienyl)tetrahydrothiophen-3-one 
4 A5 133.17 1,3-thiazolane-2-carboxylic acid 
4 B5 183.66 methyl 1,3-thiazolane-2-carboxylate hydrochloride 
4 C5 185.22 2,2-dimethyl-2H-chromene-6-carbonitrile 
4 D5 154.56 5-chloro-2,1,3-benzoxadiazole 
4 E5 144.22 (1,4-dimethyl-2-piperazinyl)methanol 
4 F5 115.17 4-piperidylmethanol 
4 G5 149.15 6-amino-1,3-dihydroisobenzofuran-1-one 
4 H5 154.21 
3-[(tetrahydrofuran-2-
ylmethyl)amino]propanenitrile 
4 A6 150.18 3-[(2-furylmethyl)amino]propanenitrile 
4 B6 152.20 3-hydroxyquinuclidine-3-carbonitrile 
4 C6 153.25 2-(methylthio)benzylamine 
4 D6 123.15 2-(3-pyridyl)ethan-1-ol 
4 E6 187.20 methyl quinoline-6-carboxylate 
4 F6 167.21 ethyl 3,5-dimethyl-1H-pyrrole-2-carboxylate 
4 G6 137.11 2-fluoro-4-hydroxybenzonitrile 
4 H6 178.23 2,2-dimethyl-N-(4-pyridinyl)propanamide 
4 A7 143.23 thiophene-3-carbothioamide 
4 B7 134.14 1,2-benzisoxazol-3-amine 
4 C7 143.17 4-Methyl-thiazole-5-carboxylic acid 
4 D7 151.21 N-(4-methoxybenzyl)-N-methylamine 
4 E7 149.24 N-(4-ethylbenzyl)-N-methylamine 
4 F7 122.17 N-methyl-N-(4-pyridinylmethyl)amine 
4 G7 177.20 methyl 2-indolinecarboxylate 
4 H7 133.15 6-amino-2-methylnicotinonitrile 
4 A8 192.26 (2-piperidino-3-pyridinyl)methanol 
4 B8 175.25 3-(2-thienyl)aniline 
4 C8 182.27 3-piperidinyl(1-pyrrolidinyl)methanone 
4 D8 182.27 4-piperidinyl(1-pyrrolidinyl)methanone 
4 E8 127.23 4-ethylcyclohexanamine 
4 F8 142.24 2-methyl-1-(1-pyrrolidinyl)-2-propanamine 
4 G8 170.30 2-methyl-1-(4-methylpiperidino)-2-propanamine 
4 H8 184.32 3-(1-azepanyl)-2,2-dimethylpropylamine 
4 A9 178.23 [2-(1-pyrrolidinyl)-3-pyridinyl]methanol 
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4 B9 177.23 5-phenyl-1,2,4-thiadiazol-3-amine 
4 C9 187.24 4-Piperazin-1-yl-benzonitrile 
4 D9 178.23 [6-(1-pyrrolidinyl)-3-pyridinyl]methanol 
4 E9 187.24 6,7,8,9-tetrahydrodibenzo[b,d]furan-2-amine 
4 F9 192.26 (Piperidino-3-pyridinyl)methanol 
4 G9 178.25 5-Methylbenzo[b]thiophene-2-methanol 
4 H9 124.14 (6-amino-3-pyridinyl)methanol 
4 A10 189.21 2,3-dimethyl-1H-indole-5-carboxylic acid 
4 B10 180.27 1-[(4-methylphenyl)thio]acetone 
4 C10 146.21 morpholine-4-carbothioamide 
4 D10 147.18 4-hydroxy-2,6-dimethylbenzonitrile 
4 E10 186.16 ethyl 3,4-difluorobenzoate 
4 F10 186.14 4-amino-2-(trifluoromethyl)benzonitrile 
4 G10 142.16 1H-indole-3-carbonitrile 
4 H10 135.12 benzo[d]isoxazol-3-ol 
4 A11 149.24 3-(tert-butyl)aniline 
4 B11 137.18 2-phenoxyethylamine 
4 C11 191.11 4-(trifluoromethyl)nicotinic acid 
4 D11 172.11 4-(trifluoromethyl)nicotinonitrile 
4 E11 186.14 6-methyl-4-(trifluoromethyl)nicotinonitrile 
4 F11 123.15 2,6-dimethylpyridin-3-ol 
4 G11 139.20 8-methyl-8-azabicyclo[3.2.1]octan-3-one 
4 H11 154.14 2-(4-fluorophenyl)acetic acid 
5 A1 175.19 2-(1H-indol-3-yl)acetic acid 
5 B1 152.19 
2-methylbicyclo[2.2.1]hept-5-ene-2-carboxylic 
acid 
5 C1 171.27 3-(pentylthio)-4H-1,2,4-triazole 
5 D1 123.15 (6-methylpyridin-2-yl)methanol 
5 E1 179.22 2-morpholinophenol 
5 F1 168.17 N-(4-fluorobenzyl)urea 
5 G1 137.14 1,3-benzodioxol-5-amine 
5 H1 151.16 2,3-dihydro-1,4-benzodioxin-6-amine 
5 A2 129.11 2,4-difluoroaniline 
5 B2 96.13 pyrrolidine-1-carbonitrile 
5 C2 117.15 1H-indole 
5 D2 153.03 2,5-dichlorothiophene 
5 E2 98.10 5-methylisoxazol-3-amine 
5 F2 183.16 
4-methyl-3-(trifluoromethyl)-4,5-dihydro-1H-
1,2,4-triazole-5-thione 
5 G2 190.12 4-(trifluoromethyl)benzoic acid 
5 H2 137.21 benzene-1-carbothioamide 
5 A3 133.15 2-(4-hydroxyphenyl)acetonitrile 
5 B3 129.16 piperidine-4-carboxylic acid 
5 C3 140.11 2-fluorobenzoic acid 
5 D3 112.10 4-fluorophenol 
5 E3 127.17 1-(1,3-thiazol-2-yl)ethan-1-one 
5 F3 126.11 3-hydroxy-2-methyl-4H-pyran-4-one 
5 G3 118.14 2-(2-pyridyl)acetonitrile 
5 H3 112.13 3,4-dimethylisoxazol-5-amine 
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5 A4 138.12 1,3-benzodioxol-5-ol 
5 B4 136.15 5-methyl-1,3-benzodioxole 
5 C4 136.15 1-(3-methylpyrazin-2-yl)ethan-1-one 
5 D4 141.60 2-chlorobenzylamine 
5 E4 149.24 4-(tert-butyl)aniline 
5 F4 177.12 2-(trifluoromethoxy)aniline 
5 G4 146.55 3-chloro-4-fluorophenol 
5 H4 153.18 2,4-dimethoxyaniline 
5 A5 127.21 2-propyl-1,3-thiazole 
5 B5 100.12 2-methyltetrahydrofuran-3-one 
5 C5 140.14 methyl 2-methyl-3-furoate 
5 D5 142.58 (2-chlorophenyl)methanol 
5 E5 125.15 4-fluorobenzylamine 
5 F5 110.11 1-(2-furyl)ethan-1-one 
5 G5 190.29 1-benzylpiperidin-4-amine 
5 H5 134.18 3,4-dihydro-1H-benzo[c]pyran 
5 A6 126.20 cyclooctan-1-one 
5 B6 134.14 1H-benzimidazol-2-ol 
5 C6 121.11 4-fluorobenzonitrile 
5 D6 165.19 N1-(2-hydroxy-5-methylphenyl)acetamide 
5 E6 123.15 3-methoxyaniline 
5 F6 147.18 2-(4-methoxyphenyl)acetonitrile 
5 G6 171.22 methyl 3-amino-4-methylthiophene-2-carboxylate 
5 H6 108.14 5-methylpyridin-2-amine 
5 A7 94.12 pyridin-4-amine 
5 B7 115.16 5-methyl-1,3,4-thiadiazol-2-amine 
5 C7 114.15 1,3-dimethylimidazolidin-2-one 
5 D7 181.07 benzene-1,3-diamine dihydrochloride 
5 E7 186.59 5-chloro-2-methoxybenzoic acid 
5 F7 171.22 2-methylbenzene-1-sulfonamide 
5 G7 120.15 2,3-dihydrobenzo[b]furan 
5 H7 122.17 N4,N4-dimethylpyridin-4-amine 
5 A8 152.24 adamantan-1-ol 
5 B8 184.07 2-(1H-imidazol-4-yl)ethylamine dihydrochloride 
5 C8 138.14 1-(3-fluorophenyl)ethan-1-one 
5 D8 100.12 tetrahydro-4H-pyran-4-one 
5 E8 151.16 2-(4-hydroxyphenyl)acetamide 
5 F8 172.13 2-(3,5-difluorophenyl)acetic acid 
5 G8 152.15 2-(2-hydroxyphenyl)acetic acid 
5 H8 177.12 3-(trifluoromethoxy)aniline 
5 A9 178.23 2-ethoxy-5-prop-1-enylphenol 
5 B9 185.70 4-isopropyl-3-methylaniline hydrochloride 
5 C9 133.19 indan-2-amine 
5 D9 176.09 2,3,4-trifluorobenzoic acid 
5 E9 100.16 1,4-diazepane 
5 F9 176.14 [2-(trifluoromethyl)phenyl]methanol 
5 G9 194.18 4-[(trifluoromethyl)thio]phenol 
5 H9 176.22 
3-(4,4-dimethyl-4,5-dihydro-1,3-oxazol-2-
yl)pyridine 
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5 A10 109.13 6-methylpyridin-2-ol 
5 B10 177.20 (S)-4-BENZYL-2-OXAZOLIDINONE 
5 C10 118.59 3-chlorothiophene 
5 D10 154.21 (2-butyl-1H-imidazol-4-yl)methanol 
5 E10 115.13 D-proline 
5 F10 138.19 2-(4-methyl-1,3-thiazol-2-yl)acetonitrile 
5 G10 141.20 2-methyl-1H-imidazole-4-carbothioamide 
5 H10 166.15 6-fluorochroman-4-one 
5 A11 184.24 thieno[3,2-b]thiophene-2-carboxylic acid 
5 B11 184.24 3-(3-methyl-1H-indol-1-yl)propanenitrile 
5 C11 191.16 2-(1-methylhydrazino)-4-(trifluoromethyl)pyridine 
5 D11 150.13 6-hydroxy-2,3-dihydrobenzo[b]furan-3-one 
5 E11 153.21 N-(4-pyridyl)thiourea 
5 F11 151.16 4,5-dihydro-1,3-benzodioxine-6-amine 
5 G11 174.24 5-(methylthio)thiophene-2-carboxylic acid 
5 H11 145.16 5-phenyl-1,3-oxazole 
6 A1 152.20 1-acetylpiperidine-4-carbonitrile 
6 B1 144.18 4-phenyl-1H-imidazole 
6 C1 153.18 methyl 2,5-dimethyl-1H-pyrrole-3-carboxylate 
6 D1 127.21 (3-methyl-2-thienyl)methylamine 
6 E1 171.22 ethyl 2-methyl-1,3-thiazole-4-carboxylate 
6 F1 124.17 2-methyl-1,3-thiazole-4-carbonitrile 
6 G1 154.14 methyl 2-fluorobenzoate 
6 H1 128.15 isoxazole-5-carbothioamide 
6 A2 142.18 5-methylisoxazole-3-carbothioamide 
6 B2 134.14 6-methyl-2-oxo-1,2-dihydropyridine-3-carbonitrile 
6 C2 134.14 6-methoxynicotinonitrile 
6 D2 153.16 N1-(2-fluorophenyl)acetamide 
6 E2 166.25 N-(2-methylphenyl)thiourea 
6 F2 124.14 2-methoxypyridin-3-amine 
6 G2 191.28 4-(4-methylpiperazino)aniline 
6 H2 177.18 5-fluoro-2-(1H-imidazol-1-yl)aniline 
6 A3 143.14 N1-methyl-2,4-difluoroaniline 
6 B3 135.21 2,3-dimethylbenzylamine 
6 C3 175.15 4-(trifluoromethyl)benzylamine 
6 D3 151.16 methyl 3-aminobenzoate 
6 E3 176.05 3,5-dichlorobenzylamine 
6 F3 167.21 2,5-dimethoxybenzylamine 
6 G3 150.18 methyl 3-methylbenzoate 
6 H3 170.59 methyl 2-chlorobenzoate 
6 A4 145.16 4-acetylbenzonitrile 
6 B4 179.22 3-morpholinophenol 
6 C4 131.18 2,6-dimethylbenzonitrile 
6 D4 149.19 2,3-dimethylbenzamide 
6 E4 142.18 methyl thiophene-2-carboxylate 
6 F4 149.19 3,4-dimethylbenzamide 
6 G4 172.59 1-(3-chloro-4-fluorophenyl)ethan-1-one 
6 H4 189.14 2-(trifluoromethyl)benzamide 
6 A5 151.19 5-acetylthiophene-2-carbonitrile 
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6 B5 187.12 2-(trifluoromethoxy)benzonitrile 
6 C5 122.17 N-methyl-N-(3-pyridylmethyl)amine 
6 D5 177.12 4-(trifluoromethoxy)aniline 
6 E5 192.14 [4-(trifluoromethoxy)phenyl]methanol 
6 F5 179.22 ethyl 2-(4-aminophenyl)acetate 
6 G5 127.21 2-(2-thienyl)ethylamine 
6 H5 132.17 2-amino-4-methylbenzonitrile 
6 A6 151.16 2-amino-4-methylbenzoic acid 
6 B6 97.12 3,5-dimethylisoxazole 
6 C6 148.20 1-(3-ethylphenyl)ethan-1-one 
6 D6 188.58 methyl 2-chloro-4-fluorobenzoate 
6 E6 136.19 (3,4-dimethylphenyl)methanol 
6 F6 170.59 3-chloro-4-methylbenzoic acid 
6 G6 150.18 methyl 2-methylbenzoate 
6 H6 184.62 methyl 3-chloro-4-methylbenzoate 
6 A7 182.24 methyl 2-(phenylthio)acetate 
6 B7 165.19 methyl 4-amino-3-methylbenzoate 
6 C7 175.23 N1-(2,3-dihydro-1H-inden-5-yl)acetamide 
6 D7 189.21 N1-(1-oxo-2,3-dihydro-1H-inden-5-yl)acetamide 
6 E7 150.18 2-amino-4-methylbenzamide 
6 F7 133.15 indolin-2-one 
6 G7 166.25 N-methyl-N-phenylthiourea 
6 H7 183.64 4-chloro-2-methylacetanilide 
6 A8 150.18 N1-(3-pyridylmethyl)acetamide 
6 B8 170.59 4-chloro-2-methylbenzoic acid 
6 C8 187.60 2-(2-chloro-4-fluorophenyl)acetamide 
6 D8 174.20 5-methyl-3-phenyl-4-isoxazolamine 
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1.A10 1.A6
 
1.A7 Ali 1.A7 Aro
 
1.B2 1.B8 Ali
1.B8 Aro 1.B9
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1.C1 Aro 1.C10
 
1.C2 1.C3
 
1.C4 1.C9
 
1.D1 1.D10
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1.E11 1.E2
 
1.E3 Aro 1.E3 Ali
 
1.E7 Aro 1.F2
 
1.F3 Ali 1.F3 Aro
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1.F6 Ali 1.F6 Aro
 
1.F8 1.G6 Ali
 
1.G6 Aro 1.G9
 
1.H1 Aro 1.H6Aro
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1.H7 1.H8 Ali
 
1.H8 Aro
 
PLATE 2 
2.A2 2.A5
 
2.B4 2.B6 Ali
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2.B6 Aro 2.B8 Ali
 
2.B8 Aro 2.C7
 
2.C9 2.D1
 
2.D10 2.D7
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2.D8 2.E1
 
2.E11 2.E8
 
2.F1 2.F3
 
2.F4 2.G5
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2.G8 2.H4
 
2.H7
 
PLATE 3 
3.B10 3.B4
 
3.B5 3.B6
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3.B9 3.C4
 
3.C5 3.D1
 
3.D6 3.E2
 
3.E7 3.E7
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3.F4Ali 3.F9
 
3.G2 3.G8
 
PLATE 4 
4.A10 4.A11
 
4.A7 4.A8
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4.A8 Ali 4.B4
 
4.B9 4.C2
 
4.C5 4.C5 Ali
 
4.D1 4.D10
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4.D4 4.D5
 
4.E1 4.E6
 
4.E6 Ali 4.F1 Ali
 
4.F1 Aro 4.F2
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4.G1 4.G5
 
4.G6 4.H4
 
4.H4 Ali 4.H6 Ali
 
PLATE 5 
5.A11 5.A4
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5.B11 5.B11 Ali
 
5.B9 5.B9 Ali
 
5.C1 Ali 5.C1 Aro
 
5.D5 5.E11
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5.F6 5.F6 Ali
 
5.F7 5.G1
 
5.G4 5.G6 Ali
 
PLATE 6 
6.A2 Ali 6.A2 Aro
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6.A5 Aro 6.B1
 
6.C7 Ali 6.C7 Aro
 
6.D8 6.E1 Ali
 
6.E1 Aro 6.F1
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6.G4 6.H1
 
6.H4 6.H5
 
6.H5 Ali
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